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Abstract 
Protein phosphorylation is controlled by protein kinases, and represents a critical 
signaling mechanism involved in the regulation of fundamental biological processes. 
Furthermore, the aberrant regulation of kinase activity is implicated in diseases such as 
cancer and has resulted in efforts to target kinases therapeutically.  Protein kinase CK2, 
although frequently considered constitutively active, has emerged as a clinical target on the 
basis of its altered expression in different types of human cancers and its regulatory 
participation in multiple biological processes.  In fact, CX-4945, a small molecule ATP-
competitive inhibitor of CK2 has advanced to clinical trial and has been widely used to 
interrogate CK2-dependent signaling events in cells. Despite its widespread applications, an 
understanding of the mechanism of action of CX-4945 on cells remains limited.  
In this thesis, comparison of proteomic sample preparation strategies led to the 
development of a phosphoproteomic workflow that enabled the enrichment of 
phosphopeptides conforming to the CK2 consensus sequence. Using the optimized workflow, 
phosphoproteomic profiling was conducted in HeLa cells treated with CX-4945. Several 
phosphorylation sites conforming to the recognition motif for CK2 phosphorylation 
displayed significantly decreased phosphorylation in response to CX-4945. Kinase substrate 
enrichment analysis also revealed a broad impact of CX-4945 on several kinases other than 
CK2.  Profiling of the kinome utilizing multiplexed inhibitor beads also revealed changes in 
the activity of other kinases including activation of the ERK MAPK pathway and inhibition 
of the PI3K/Akt/mTOR pathway.  Studies with Inhibitor VIII, an unrelated CK2 inhibitor, 
also resulted in activation of the ERK MAPK pathway suggesting that CK2 has a role in 
regulating this pathway.  By comparison, the PI3K/Akt/mTOR pathway was not affected by 
  iii 
Inhibitor VIII indicating that the effects of CX-4945 on that pathway are independent of 
CK2. 
Overall, this investigation provides valuable insight into the regulation of the 
phosphoproteome and the kinome in response to CX-4945 in HeLa cells. Dynamic markers 
of CK2 activity in cells were identified and putative CK2-independent effects of CX-4945 
were revealed.  Collectively, these studies illustrate the utility of global proteomic 
approaches to elucidate the cellular effects of clinical-stage kinase inhibitors.  
 
Keywords: CK2, proteomic, phosphorylation, CX-4945, kinase inhibitors, mass 
spectrometry 
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1 Chapter 1 – Introduction 
1.1 General Introduction1 
The reversible phosphorylation of cellular proteins that is catalyzed by protein kinases 
represents a central mechanism for the transmission of intracellular signals (1). In eukaryotes, 
protein kinases catalyze the transfer of phosphate from ATP to the hydroxyl group located on 
side chains of amino acids serine, threonine and tyrosine. The phosphate group can be 
removed by a specific phosphatase when no longer required (2). Phosphorylation plays a 
pivotal regulatory role in a broad array of cellular responses including activation of 
transcription factors (3), conformational change in protein structure (4), and the mediation of 
protein-protein interactions which comprise signal transduction pathways (5). Approximately 
700,000 potential phosphorylation sites could exist in the human proteome (6), with nearly 
three quarters of proteins that are detectable by mass spectrometry being phosphorylated, 
demonstrating the widespread impact of phosphorylation in maintaining cellular processes 
(7). Not surprisingly, because of the critical role in regulatory signaling pathways, the 
deregulation of kinases can lead to pathophysiological processes such as cancer (8) and has 
prompted interest in kinases as drug targets for cancer therapeutics (9). 
1.2 Protein Kinase CK2 
Protein kinase CK2 represents one small protein kinase family that has recently 
emerged as a potential therapeutic target based on alterations in its expression or activity in a 
number of cancers (10).  CK2 is composed of two closely related catalytic isoforms CK2α 
                                                
1 Excerpts of this chapter are reproduced with permission from: 
Rabalski, A. J., Gyenis, L., and Litchfield, D. W. (2016) Molecular Pathways: Emergence of 
Protein Kinase CK2 (CSNK2) as a Potential Target to Inhibit Survival and DNA Damage 
Response and Repair Pathways in Cancer Cells. Clin. Cancer Res. 22, 2840–2847 
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and CK2α’ (encoded by CSNK2Α1 and CSNK2A2 genes respectively) that both display 
catalytic activity in the presence or absence of its regulatory CK2β (CSNK2Β) subunit. The 
regulatory CK2β subunit is not essential for activity, but can impact the ability of the 
catalytic subunits to phosphorylate certain substrates (11). CK2 has also been shown to be 
essential for viability, as deletion of CK2α or CK2β leads to embryonic lethality in mice (12, 
13). A recent analysis of transcript expression profiles for CSNK2A1, CSNK2A2 and 
CSNK2B in neoplastic tissues versus normal tissues deposited in the Oncomine database 
revealed varying degrees of altered expression of individual CK2 subunits suggesting that 
deregulation of CK2 subunit expression profiles promotes cancer (14).  To this point, the 
CK2-dependent phosphoproteome has not yet been fully elucidated and the impact of 
alterations in CK2 on the phosphoproteome has not yet been systematically investigated.  
Nevertheless, it is evident both from an extensive literature and computational predictions of 
its substrates based on its consensus recognition motif (S/T-X-X-D/E/pS/pY) that CK2 could 
be implicated in a vast landscape of biological processes (Figure 1.1) with >2000 putative 
phosphorylation sites in the human proteome (15). While more comprehensive discussions of 
CK2 can be found elsewhere (16, 17), we will highlight the involvement of CK2 in specific 
cellular processes, including its convergence with caspase pathways and its roles in DNA 
response and repair pathways, which have inspired ongoing efforts to exploit CK2 as a 
therapeutic target. 
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Figure 1.1 Protein Kinase CK2 is Implicated in Different Biological Processes 
CK2 (referred to as CSNK2 in the figure) is presented with examples of putative substrates 
or interacting proteins involved in each biological process listed. These proteins were 
identified using gene ontology biological processes according to the following databases: 
UniProt, Reactome, PHOSIDA and PubMed. This figure is reproduced with permission from 
AACR. 
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1.3 Convergence of CK2 with Caspase Pathways 
CK2 is generally considered to be a constitutively active enzyme (ie. its catalytic subunits do 
not require activating phosphorylation, association with its regulatory subunit or the presence 
of second messengers to be catalytically active), which is expressed at higher levels in many 
forms of human cancer (14, 18-20). These observations are particularly intriguing when 
considering the remarkable resemblance of the consensus recognition motif of CK2 with that 
of caspases (Figure 1.2 A) which cleave substrates at aspartic acid residues during the 
progression of apoptosis. In fact, several published examples (Figure 1.2 A) demonstrate that 
caspase substrates, including Bid which promotes apoptotic progression when it is cleaved, 
can be phosphorylated by CK2 at sites adjacent to caspase cleavage sites.  Since 
phosphorylation adjacent to caspase cleavage sites blocks cleavage, these observations 
suggest that increased phosphorylation by CK2 could promote cell survival by inhibiting 
caspase action (21-26).  
Building on these observations, a combined computational and biochemical approach 
revealed an extensive repertoire of proteins with overlapping CK2 and caspase recognition 
motifs suggesting that CK2 could have widespread impact on caspase action (27).  In 
addition to the identification of many proteins known to be caspase substrates, these studies 
also demonstrated that CK2 could phosphorylate caspase-3 to prevent its cleavage by 
upstream caspases activated by intrinsic and extrinsic apoptotic stimuli (Figure 1.2 A).  
Collectively, these findings demonstrate that CK2 has the potential to inhibit caspase action 
at both the level of caspase activation and cleavage of downstream substrates.  Furthermore, 
these findings raise the prospect that the higher (ie. pathological) levels of CK2 that are 
observed in cancer cells could result in the pathological rewiring of caspase pathways to 
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promote cell survival.  Interestingly, further characterization of the relationship between CK2 
and caspases revealed intriguing isoform specificity. In this respect, caspase-3 appears to be 
preferentially phosphorylated by CK2α’ rather than CK2α despite the fact that these two 
isoforms of CK2 have very similar enzymatic characteristics (33). Furthermore, CK2β 
attenuated phosphorylation suggesting that misregulation of CK2 subunits in cells could be 
an additional mechanism to affect the regulation of apoptosis (24).  The capacity of CK2 to 
promote cancer cell survival in vitro was also revealed in a recent large scale screen utilizing 
RNAi knockdown and cDNA overexpression of kinases in DLD-1 colorectal 
adenocarconima cells where overexpression of CK2α promoted resistance to TRAIL as 
determined by flow-cytometry utilizing antibodies against cleaved PARP and cleaved 
caspase-3 (34).  Overall, while CK2 is only one of many constituents that intersect caspase 
pathways, its ability to modulate caspase action through phosphorylation of caspase 
substrates (potentially including caspases themselves) represents one potential mechanism by 
which CK2 might be exploited to neutralize cancer cell survival.     
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Figure 1.2 CK2 in the Control of Cell Survival and Response to DNA Damage 
A) On the basis of the remarkable similarity of the consensus recognition motifs for 
phosphorylation by CK2 (S/T-D-X-X-D/E) and cleavage by caspases (E-X-D), it is evident 
that there are many cellular proteins where CSNK2 phosphorylation could occur adjacent to 
caspase cleavage sites to block their cleavage by caspases (27). B) Proteins shown here are 
involved in DNA damage repair, which requires phosphorylation by CK2 to execute 
respective DNA repair processes. A recurring theme with the illustrated proteins (i.e., 
MDC1, RAD51, and TCOF1) is the ability of CK2 to promote phosphorylation-dependent 
interactions with the FHA domain of the NBN component of the MRN complex (28-32). 
Reproduced with permission from AACR. 
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1.4 CK2 and DNA Damage Response & Repair Pathways 
 Another manner in which CK2 may contribute to the regulation of cancer cell 
survival that might be exploited for intervention is through its involvement in DNA damage 
response (DDR) and DNA repair pathways (Figure 1.2 B).  In this respect, recent large-scale 
phosphoproteomic analyses of G361 melanoma cells and GM00130 B lymphocyte cells 
treated with the radiomimetric drug neocarzinostatin or with ionizing radiation to induce 
DNA double-stranded breaks (DSBs) respectively, demonstrated a dynamic response in 
motifs preferential for CK2 phosphorylation in many proteins. These results reveal a 
previously under-appreciated role for CK2 as an important mediator in the cellular response 
to DSBs (35, 36).  Other indications that CK2 is involved in DDR and DNA repair pathways 
include the demonstration that CK2α localizes to perinuclear structures whereas CK2α’ 
becomes nuclear in response to DSBs caused by ionizing radiation (37). Some of the putative 
CK2 substrates that are involved in DDR are scaffold proteins such as mediator of DNA 
damage checkpoint 1 (MDC1), where phosphorylation of serine-aspartate-threonine repeats 
regulates retention of the MRE11A-RAD50-NBN (MRN) complex at DSBs through 
interactions with Forkhead-associated (FHA) domains in the NBN (Nijmegen breakage 
syndrome protein 1) component of the MRN complex (28, 29). Another critical interaction 
for NBN is co-localization to the nucleolus which is dependent on the phosphorylation of 
TCOF1 by CK2 at threonine 210, independent of MRE11A (30, 31). In terms of regulating 
processes tasked with repairing damaged DNA, the phosphorylation of XRCC1 by CK2 is 
required for single-strand break repair (38) and phosphorylation of XRCC4 is necessary for 
non-homologous end joining repair (39). In homologous recombination, phosphorylation of 
RAD51 by PLK1 at serine 14 primes the phosphorylation of threonine 13 by CK2, regulating 
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binding to the NBN component of the MRN complex and facilitating recruitment of RAD51 
to damaged DNA (32). In another recent study, it was determined that the phosphorylation of 
a deubiquitylase OTUB1 by CK2 is necessary for its nuclear accumulation in order to 
promote the formation of TP53BP1 repair foci at DSBs (40).  While there are undoubtedly 
many details regarding its roles in DDR and DNA repair pathways that remain to be 
elucidated, these examples demonstrate that CK2 may have an important role in several 
discrete aspects of these processes. A recurring theme that is highlighted by these examples 
is that phosphorylation by CK2 promotes phosphorylation-dependent interactions such as 
those involving the FHA domain of the NBN component of the MRN complex. Overall, the 
widespread involvement in these processes could be relevant to the development of strategies 
that neutralize the advantages or exploit the unique vulnerabilities of cancer cells. 
1.5 Protein Kinase CK2 Inhibitors 
As CK2 is implicated in a number of fundamental biological processes, and found at 
varying levels of deregulation in human cancers, there has been widespread interest in 
targeting this kinase therapeutically (10, 14). While there are many inhibitors described in the 
literature (41, 42), the following sections focus on the use of CX-4945.  
1.5.1 CX-4945: an ATP-competitive CK2 Inhibitor in Clinical Trial  
CX-4945 was developed by Cylene Pharmaceuticals Inc. and is a potent and selective 
ATP-competitive inhibitor (Ki = 0.38 nM for CK2α and CK2α’ with an IC50 of 1 nM) with no 
extensive inhibitory activity detected against a panel of 238 kinases (43, 44). 
Characterization of its in vitro effects revealed varying degrees of activation of caspase 3 and 
caspase 7 in cancer cells with no detectable change of caspase 3/7 activity in normal cells 
(44). Interestingly, CX-4945 elicited differential effects on the cell cycle with BT-474 breast 
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cancer cells arresting in G2/M transition and BxPC-3 prostate cancer cells arresting in G1 
(44). In vitro studies employing CX-4945 in combination with gemcitabine or cisplatin 
revealed enhanced anti-proliferative effects in A2780 and SKOV-3 ovarian cancer cells.  
Anti-proliferative activity was 23-38% higher based on a Bliss Independence model when 
CX-4945 was added to cells after treatment with gemcitabine or cisplatin. These treatments 
were also accompanied by decreased phosphorylation of the CK2 substrates XRCC1 and 
MDC1 and accumulation of single-stranded and double-stranded DNA breaks (45). These 
data are in agreement with the observations of CK2 localizing to the nucleus in response to 
double-stranded breaks and for the role of CK2 in the DDR and DNA repair mechanisms (37, 
38, 46, 47). Currently CX-4945 is in Phase I/II clinical trial in the U.S., South Korea and 
Taiwan for the treatment of cholangiocarcinoma (bile duct cancer) in combination with 
gemcitabine and cisplatin (ClinicalTrials.gov Identifier NCT02128282). The aim of this trial 
is to determine its maximum tolerable dose in patients followed by a randomized Phase II 
assessment using CX-4945 in combination with gemcitabine and cisplatin versus the 
standard of care. 
1.5.2 Emerging Prospects for Combinatorial Treatments Involving CK2 Inhibition  
CX-4945 has been used in combination with other agents and has shown promise for 
targeting a number of malignancies. For example, CX-4945 has been studied in vitro in 
combination with DNA-damaging agents such as in acute myeloid leukemia cell lines and 
patient-derived leukemia cells (48). In another study of hematological malignancies, CX-
4945 demonstrated a significant decrease in cell viability of patient-derived chronic 
lymphocytic leukemia (CLL) cell lines in vitro (49). When CX-4945 was combined with GS-
1101 (PI3KD inhibitor), ibrutinib (BTK inhibitor), or fludarabine, synergistic responses were 
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observed in CLL cell lines that were not observed in the unpaired treatments with 
combination indices (using the Chou-Talalay method) of 0.46, 0.56 and 0.30 for CX-4945 
and GS-1101, ibrutinib and fludarabine, respectively. Combinations of CX-4945 and 
bortezomib using patient-derived cells from multiple myeloma and mantle cell lymphoma 
also demonstrated enhanced mitochondria dependent apoptosis associated with suppression 
of NFKB1 and STAT3 target genes leading to 50% reduction of NOS2 and BCL2 gene 
expression (50). In other in vitro cell models of cancer such as A431 epidermal carcinoma 
cells and H2170 lung cancer cells, combining erlotinib and CX-4945 resulted in suppression 
of Akt1 phosphorylation in addition to down-regulation of phosphorylation sites on Akt1 and 
mTOR substrates (51). Combined treatment resulted in 3-fold increases in apoptosis as 
determined by caspase-3 and caspase-7 activity assays in comparison to treatment by CX-
4945 or erlotinib alone. This enhanced anti-proliferative effect was also demonstrated in 
mouse xenograft models with the greatest reduction in tumor volume resulting from 
combined treatment in both A431 and H2170 xenograft mice (51).  
Since resistance is commonly observed with both chemotherapy and targeted therapy 
involving kinase inhibitors, inhibition of CK2 has also been explored as a strategy for 
overcoming both de novo resistance and acquired resistance. Analysis of several multidrug-
resistant cell lines revealed that CX-4945 sensitized cells to vinblastine and doxorubicin, 
resulting in reduction of cell viability by 50% when treating with vinblastine and a two-fold 
increase in doxorubicin accumulation in resistant cells (52). These results indicate that CK2 
inhibition may have utility for over-coming de novo resistance. 
There is also mounting evidence to suggest that CK2 inhibition may be effective to 
combat adaptive resistance. Investigation of imatinib-resistant chronic myeloid leukemia cell 
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lines revealed two-fold higher protein and activity levels of CK2, along with increased 
localization of CK2α and CK2β to the cytoplasm of imatinib-resistance cells in comparison 
to imatinib-sensitive cells (53). Interestingly, treatment with CX-4945 abrogated CK2α and 
Bcr-Abl interaction as determined by co-immunoprecipitation and glycerol gradient 
sedimentation leading to the induction of apoptosis in resistant cell lines at concentrations 
that failed to promote PARP cleavage in imatinib-sensitive CML. Furthermore, treatment of 
imatinib-resistant CML cells with CX-4945 or siRNA targeting CK2α promoted higher 
sensitivity to lower concentrations of imatinib, suggesting that the kinome had adapted in 
response to Bcr-Abl inhibition by imatinib leading to increased dependence on CK2 activity 
(53). In an in vitro cell model of T-cell acute lymphoblastic leukemia, CX-4945 
downregulated the unfolded protein response as determined by HSPA5 expression and 
caused increased ERN1, phosphorylated EIF2S1, and DDIT3 indicating ER stress. When 
paired with thapsigargin or temsirolimus the synergistic cytotoxicity was further potentiated 
in these cell based assays (54). More recently, analysis of acquired resistance in triple 
negative breast cancer using SUM149 and SUM159 cell lines revealed that resistance to the 
BET bromodomain inhibitor JQ1 was associated with increased binding of BRD4 to MED1 
in a bromodomain-independent manner, and dependent on BRD4 phosphorylation by CK2α, 
which keeps transcriptional regulation of genes promoting cellular proliferation active (55). 
Utilization of CK2 inhibitor or protein phosphatase PP2A activators such as perphenazine 
decreased phosphorylation of BRD4, suggesting a rationale combination for tackling BET 
bromodomain inhibitor resistance in triple negative breast cancer. Collectively, these 
observations raise the prospect that CK2 inhibitors could be utilized to enhance the 
effectiveness of other interventions.  
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1.6 Mass Spectrometry-Based Proteomics 
The study of the protein-encoded complement of the genome on a global scale is referred to 
as proteomics. This analysis also includes the corresponding factors that can regulate protein 
function, such as posttranslational modifications and abundance. Mass spectrometry-based 
proteomics takes advantage of the ability to acquire high quality spectra of analyte derived 
from protein sources in complex samples such as human cells or tissue (56). This analysis 
can be accomplished rapidly with current mass spectrometry instrumentation enabling the 
identification of thousands of proteins in a limited amount of time (57). The most common 
form of mass spectrometry-based proteomics is the “bottom up” approach, where proteins are 
digested by proteases resulting in short peptides that are then analyzed (Figure 1.3). Peptides 
are delivered to the mass spectrometer using micro or nano-scale high-performance liquid 
chromatography columns. Peptides injected onto the column are eluted using an increasing 
gradient of organic solvent which separates the peptides on the basis of hydrophobicity when 
using stationary matrices such as reversed-phase C18 material. The eluted peptides are then 
ionized at the point of entry to the mass spectrometer by the application of electric potential 
across an emitter needle, using a process called electrospray ionization (58). The ionized 
peptides are measured on the basis of their mass-to-charge (m/z) ratio. In data-dependent 
analysis, peptide ions are detected and analyzed typically in two stages. In the first stage 
(MS1), the mass analyzer performs a survey scan selecting specific precursor ions, usually on 
the basis of abundance. These selected precursor ions are then fragmented in a collision cell 
and detected in a second mass analyzer (MS2). A commonly used fragmentation mode, 
collision-induced dissociation (CID), creates ion fragments through collisions with inert gas 
molecules, generating ions that originate from the amino terminus (b ions) and carboxy 
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terminus (y ions). The basis of peptide sequence identification results from the calculation of 
the differences in mass observed between fragment ions, which can represent an amino acid 
(59).  The assigned precursor and fragment masses can then be searched against a database to 
identify the sequence and can be statistically validated using decoy search strategies to 
estimate the rate of false positive identification (reviewed in (60, 61)). A complete review of 
the mass spectrometry instrumentation and technology used to generate data presented in this 
thesis is beyond the scope of this thesis and can be found in (62-64). 
1.7 Quantitative Proteomics 
Quantitative proteomic strategies can be employed to better understand the context of the 
biological system being analyzed. This approach moves away from simply identifying a 
protein of interest using mass spectrometry towards an approach that enables characterization 
of dynamic features of the protein or system of interest. Quantitative strategies can be applied 
at the protein or peptide level. Labeling techniques such as isobaric tags for relative and 
absolute quantitation (iTRAQ) (65), tandem mass tags (TMTs) (66), or dimethyl labeling 
(67) are performed at the peptide level. This results in peptides that can be distinguished in a 
mass spectrometer between different conditions or treatments. A commonly used approach 
involves labeling at the protein level in vivo in the system of interest. Stable isotopic labeling 
of amino acids in cell culture (SILAC) involves the metabolic labeling of amino acids 
containing 13C or 15N into the proteome of a cell (68, 69). By using arginine and lysine amino 
acids that are labeled with “heavy” 13C or 15N isotopes and a protease such as trypsin that 
cleaves after the c-terminus of arginine and lysine residues, one can obtain a sample where 
theoretically all peptides are labeled (Figure 1.4). SILAC-labeled samples are mixed at a 1:1 
ratio at the protein level prior to sample digestion and handling. This ensures that samples 
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that were differentially treated within the biological context of interest undergo the same 
handling steps and minimizes the likelihood of sample loss in one label versus the other. 
Peptides from SILAC samples elute at the same time during chromatographic analysis, and 
are distinguishable due to the difference in mass introduced by the presence of “heavy” 
amino acid. The abundance of a peptide can then be determined by relative quantitation. 
MaxQuant, a freely available mass spectra data analysis software can detect the three-
dimensional characteristics of a SILAC pair in MS1 using m/z, signal intensity and elution 
time, enabling the accurate identification and quantitation of thousands of peptides detected 
in an LC-MS/MS acquisition (70, 71). 
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Figure 1.3 Identification of Peptides Using Mass Spectrometry 
Peptides generated from protein samples using proteases such as trypsin can be ionized using 
electrospray ionization and delivered into the mass spectrometer by liquid chromatography. 
Ions are selected on the basis of abundance in MS1 during data-dependent analysis, and 
fragmented for detection in MS2. CID fragmentation results in b and y ions. The difference 
in mass from the resulting fragments can be used to identify the amino acid sequence of the 
peptide. 
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Figure 1.4 Quantitative Proteomics Using SILAC 
SILAC enables the labeling of proteins in cellular systems using amino acids containing 13C 
and 15N isotopes. When arginine and lysine amino acids are used as the source of metabolic 
labeling, proteolytic cleavage using trypsin will result in a sample of peptides that are labeled 
with a “heavy” amino acid at the carboxy-terminus. SILAC labeled peptide pairs will elute at 
the same time during liquid chromatography separation, and will be distinguishable in the 
mass spectrometer due to the labeled amino acid-specific mass shift. Relative quantitation is 
achieved during MS1 where a ratio can be calculated based on the intensity of each peptide 
ion peak. Detection of peptide ion fragments in MS2 ensures appropriate sequence 
identification.  
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1.8 Phosphoproteomics 
Phosphorylation is a posttranslational modification which can be dynamically 
regulated through kinases and phosphatases. Quantitative phosphoproteomic strategies have 
been successfully employed to study signaling networks involved in cell cycle regulation 
(72) and the response to kinase inhibitors (73). Due to the nature of data-dependent 
acquisition where peptide ions are selected based on abundance, unphosphorylated peptides 
typically predominate the peptides selected for fragmentation and MS2 detection, therefore 
limiting the analysis of phosphopeptides (74). Consequently, phosphopeptide enrichment 
strategies are typically required to overcome this obstacle and enable detection of 
phosphopeptides. One commonly used enrichment strategy is metal oxide affinity 
chromatography using TiO2, which captures phosphopeptides through the interaction of the 
phosphate anion in a “bridging-bidentate” mode with TiO2 (75). The selectivity of 
enrichment is further enhanced by using acid modifiers such as lactic acid (76),  during 
washes and incubation steps which prevent the binding of non-phosphorylated peptides 
through carboxylic groups. When coupled with a quantitative label such SILAC, the relative 
comparison of the abundance of a phosphopeptide can enable the quantitation of 
phosphorylated residues (referred to as phosphorylation sites) localized to that peptide. 
Bioinformatics approaches can then be employed to assign kinase-substrate relationships 
using linear motifs (77). A recent comprehensive review of phosphoproteomic strategies and 
workflows is described in (78). 
1.9 Chemical Proteomic Approaches to Study the Kinome 
In addition to the development of phosphoproteomic profiling to monitor the phosphorylation 
status of protein kinase substrates, complementary strategies have emerged to directly 
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monitor the kinome. The capture of kinases using chemical biology approaches was first 
demonstrated using adenosine-5’-(γ-4-aminophenyl)triphosphate-sepharose affinity 
chromatography to isolate MEK from rabbit skeletal muscle (79). This approach was further 
advanced using ATP-competitive inhibitors to identify targets of cyclin dependent kinase and 
glycogen synthase kinase-3, demonstrating the utility of this methodology to profile off-
target effects of kinase inhibitors (80, 81). Studies expanding on the types of inhibitor resins 
available for chromatography have devised combinations of inhibitors that achieve broad 
capture and selective capture of kinases. These latter developments have enabled the 
identification of the broad impact of kinase inhibitors on the kinome and revealed target 
profiles of clinical stage inhibitors (82). Quantitative applications using SILAC labeling have 
also been used to monitor the changes in the phosphorylation status of the kinome during the 
cell cycle, identifying regulated phosphorylation sites on kinases that were previously 
uncharacterized in the regulation of the cell cycle (83). Building on this approach, 
optimization of the kinase inhibitor mix utilized by Daub et al. (83) led to the development of 
the Multiplexed Inhibitor Bead (MIB) protocol by Duncan et al. (84). MIBs have been used 
as a means to capture and infer the activity of hundreds of active kinases (ie. the active 
kinome) from cell extracts.  With triple-negative breast cancer cells and mouse models, this 
approach revealed activation of receptor tyrosine kinases such as PDGFRβ and DDR1 in 
response to the MEK inhibitors selumetinib or trametinib, which in turn activated 
downstream kinases capable of activating the MAPK pathway through an alternative route to 
circumvent inhibition (84).  
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1.10 Rationale for Study 
With recent advances in mass spectrometry-based proteomics and the increased 
sophistication of computational approaches, it is now possible to explore cellular responses 
to kinase inhibition on a proteome-wide scale.  In addition to identification of direct targets 
of individual kinases within cells, phosphoproteomic studies are also revealing new 
relationships between different kinases or kinases-mediated pathways within the complex 
and intricate regulatory networks that orchestrate cellular processes.  For example, in a 
thyroid cancer cell line harboring the BRAF V600E mutation, phosphoproteomic analysis 
following short-term treatment (15 or 30 minutes) with vemurafenib (PLX4032) or MEK 
inhibitor selumetinib (AZD6244) revealed increased phosphorylation of numerous sites. 
Interestingly approximately 50% of the up-regulated sites conformed to the CK2 consensus 
motif suggesting that CK2 activity is impacted by inhibition of MAPK signaling (85).  
Building on that observation, combination of CX-4945 with vemurafenib demonstrated a 
synergistic effect in reducing cell viability by 60% in V600E mutant thyroid cancer cells and 
in mutant melanoma cell lines. In another global phosphoproteomic study, CK2 
phosphorylation sites had increased phosphorylation site stoichiometry in gefitinib-resistant 
PC9 lung cancer cells in comparison to gefitinib-sensitive cells, in addition to having higher 
phosphorylation stoichiometry than MAPK or EGFR regulated phosphorylation sites (86). 
Collectively, these large-scale phosphoproteomics studies imply that CK2 may have an 
important role in drug resistance mechanisms and offers new insights regarding pathways 
that may be regulated or influenced by CK2.  
In this respect, applications of proteomic and phosphoproteomic strategies for 
profiling CK2 inhibitors would undoubtedly be invaluable in assessing the prospect of 
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resistance to CK2 inhibition and revealing the relationships of CK2 with other constituents of 
the regulatory kinase networks. Given the emergence of CX-4945 as a clinical-stage 
inhibitor, it has become widely used in the CK2 field to study cellular processes that CK2 is 
implicated in regulating. Therefore, an investigation into effect of CX-4945 on a global scale 
is warranted, and characterization of the effects of CX-4945 in an unbiased manner will 
highlight the CK2-dependent and independent effects in cells. 
1.11 Thesis Objective 
In chapter 2, development and optimization of a phosphoproteomics workflow was 
performed. We identified that the use of specific types of sorbents for sample preparation can 
impact the ability to enrich for phosphopeptides that match the CK2 consensus. We also 
compared workflows to evaluate the utility of using chromatographic separation to 
fractionate phosphopeptide mixtures prior to LC-MS/MS analysis and demonstrated that 
fractionation did not dramatically improve the detection of phosphopeptides and that 
omission of the chromatographic fractionation has the advantage of reduced sample handling 
and instrument time. The sample preparation protocol was further refined by comparing two 
different methods for proteolytic digestion of protein samples, with one method 
outperforming the other in the number of phosphorylation sites identified.  
In chapter 3, we performed unbiased phosphoproteomic profiling of the effect of CX-
4945 on HeLa cells using a quantitative SILAC strategy. This resulted in the identification of 
several dynamic markers of CK2 activity that displayed larger magnitudes of de-
phosphorylation in comparison to a bona fide substrate, EIF2S2 Ser2 that has been 
previously utilized as a biomarker for CK2 activity. CK2 phosphorylation sites were located 
on several proteins involved in DNA repair and translation, highlighting the importance of 
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CK2 in regulating these processes. Overall, interrogation of the phosphoproteome revealed a 
broad impact on several kinases when kinase-substrate enrichment analysis was performed, 
suggestive of both CK2-dependent and CK2-independent effects of CX-4945 in cells.  
In chapter 4, we performed MIB profiling of the kinome in HeLa cells to corroborate 
the phosphoproteomic data. This resulted in the identification of kinases downstream of 
PI3K/Akt/mTOR pathway that are down regulated by CX-4945 treatment, and the 
demonstration that the ERK MAPK pathway is activated following CX-4945 treatment. 
Further studies were performed with an unrelated inhibitor of CK2, “Inhibitor VIII,” (Figure 
1.5).  These studies revealed that CX-4945 and Inhibitor VIII have some overlapping effects 
but also putative divergent functions. In this respect, treatment with either CK2 inhibitor 
resulted in activation of ERK whereas inhibition of the mTOR pathway was exclusively 
observed with CX-4945. Additional characterization using flow cytometry and western 
blotting revealed differential effects of these two inhibitors in cells, raising speculation about 
the mechanism of action in cells.  
Taken together, the proteomic characterization of cells treated with CX-4945 has 
identified dynamic markers of CK2 activity and also revealed the broad impact of CX-4945 
on the phosphoproteome which suggests that CK2 is intricately involved in regulatory kinase 
networks and that CX-4945 may also elicit CK2-independent effects in cells. 
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Figure 1.5 Structures of ATP-competitive CK2 Inhibitors CX-4945 and Inhibitor VIII 
CX-4945 (5-((3-chlorophenyl)amino)benzo[c][2,6]naphthyridine-8-carboxylic acid) is 
described in (43, 44). Inhibitor VIII (4-(2-(4-methoxybenzamido)thiazol-5-yl)benzoic acid) is 
described in (87).  
 
 
 
 
 
  
23 
2 Chapter 2 – Development of a Mass Spectrometry – Based Phosphoproteomics 
Workflow 
2.1 Introduction 
The phosphorylation of proteins by protein kinases is a critical post-translational 
modification required in the regulation of cellular homeostasis (88). Advances in mass 
spectrometry have enabled not only the identification of phosphorylation sites but the 
quantitative dynamics of this modification on a large scale (89). However, enrichment 
strategies are still required in order to detect phosphorylated peptides and different options 
exist such as immobilized metal ion affinity chromatography using iron (Fe3+) (90) or metal 
oxide affinity chromatography using TiO2 (91). 
Protein kinase CK2 is involved in a multitude of cellular processes by virtue of the number of 
proteins that it can phosphorylate and is necessary for cell survival and proliferation (16). 
The specificity determinants of protein kinase CK2 dictate the phosphorylation of target 
protein substrates, with acidic residues such aspartic acid or glutamic acid in the n + 3 
position (relative to the phospho-acceptor residue) serving as critical elements (92-95). 
Bioinformatic analyses have demonstrated that in addition to the n +3 position, CK2 
substrates generally display large stretches of acidic residues rendering sequences 
hydrophilic in nature (15). Contemporary sample preparation methods in phosphoproteomic 
workflows require steps for desalting of peptides prior to phosphopeptide enrichment (96, 
97). The use of reverse-phased columns for desalting can affect the recovery of hydrophilic 
peptides (98, 99). This poses a challenge for the detection of phosphorylated peptides that are 
putative substrates of CK2. Therefore, the investigation of different solid phase extraction 
(SPE) columns for peptide desalting was undertaken to determine if phosphorylated 
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hydrophilic peptides containing a CK2 consensus sequence could be retained and later 
detected by LC-MS/MS. A comparison of porous graphitic carbon (PGC) and octadecyl 
carbon chain (C18) SPE columns was undertaken in combination with a strong cation 
exchange chromatography (SCX) fractionation workflow (Figure 2.1). This resulted in the 
generation of four datasets: phosphopeptides from samples fractionated using SCX and 
without fractionation, respectively desalted by PGC and C18 SPE columns. Integrating a 
combined PGC and C18 SPE desalting step, the phosphoproteomic workflow was further 
developed by comparing the preparation of protein lysates using Filter Aided Sample 
Preparation (FASP) or protein precipitation (PP) prior to phosphopeptide enrichment. This 
enabled the evaluation of the respective protein preparation methods and their respective 
effect in identifying phosphorylation sites and protein groups reproducibly.  
  
25 
 
 
Figure 2.1 Schematic for Comparison of Phosphopeptide Enrichment Workflows. 
Lysate from UTA6 cells was digested in-solution with trypsin and desalted with PGC or C18 
SPE columns. 75% of peptides were fractionated by SCX chromatography prior to 
phosphopeptide enrichment with TiO2 and 25% were directly enriched for phosphopeptides 
using TiO2. All samples were analyzed by LC-MS/MS using a QExactive mass spectrometer 
operated in data-dependent acquisition mode and resulting raw spectra were analyzed in 
PEAKS 7.0. 
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2.2 Results 
2.2.1 Evaluation of PGC and C18 SPE for Phosphopeptide Identification 
A comparative analysis of phosphopeptides derived from peptide mixtures that were 
desalted by PGC or C18 SPE columns was performed to investigate the utility of 
fractionation for a phosphoproteomics workflow. Analysis of unique variants of 
phosphopeptides in PEAKS software (non-unique amino acid sequences, but unique patterns 
of variable modifications) that were detected by LC-MS/MS revealed distinct but 
overlapping sets of phosphopeptide identification between PGC and C18 SPE desalted 
samples (Figure 2.2). PGC SCX-TiO2 yielded more phosphopeptides than C18 SCX-TiO2, 
identifying a total of 3118 phosphopeptides of which 338 were shared by the C18 SCX-TiO2 
method that in total only yielded 678 phosphopeptides. When comparing the respective SPE 
sorbents with or without SCX fractionation, both the PGC and C18 methods without 
fractionation outperformed the SCX-fractionation method in terms of phosphopeptide yield. 
C18 TiO2 yielded 4,402 phosphopeptides identified, exceeding that of PGC TiO2 that 
identified 3,842 phosphopeptides, with 1,560 phosphopeptides shared between the two 
methods. Considering the increased yield of phosphopeptides from workflows without SCX 
fractionation and the increased complexity of the SCX-fractionation workflows that require 
multiple desalting steps in contrast to the single step desalt with the unfractionated samples, 
we focused the comparison of phosphopeptides from unfractionated samples desalted with 
PGC and C18.  
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2.2.2 Comparison of Phosphorylation Motifs Obtained from PGC and C18 SPE 
 To compare the utility of PGC and C18 SPE columns for desalting tryptic digests 
prior to phosphopeptide enrichment for the identification of hydrophilic phosphopeptides that 
could be putative phosphorylation sites by CK2, we analyzed the phosphopeptides obtained 
from the phosphoproteomic workflows using a bioinformatics tool, motif-x (100, 101). 
Statistically significant over-represented motifs from modified serine residues were identified 
in each of the samples (Figure 2.3). Both SPE columns retained phosphopeptides that were 
enriched for phosphorylation motifs containing proline in the n +1 with comparable 
performance based on the fold increase.  However, the PGC SPE column exhibited the best 
performance in the  identification of acidic motifs reminiscent of the specificity determinants 
of CK2 with two motifs matching the CK2 consensus sequence being enriched 61.87-fold 
and 49.47-fold over the background frequency of serine residues in the human proteome. 
This result demonstrates the utility of a different sorbent to achieve desalting prior to 
phosphopeptide enrichment as opposed to a silica-based C18 reverse-phase material for the 
purposes of identifying phosphopeptides that display the specificity determinants for 
phosphorylation by CK2.  
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Figure 2.2 Comparative Analysis of Phosphopeptides Identified Using Different Sample 
Preparation Workflows 
Phosphopeptides enriched from SCX-fractionated and unfractionated samples using TiO2 
were analyzed by LC-MS/MS and searched in PEAKS 7.0. Phosphopeptide variants (unique 
modification pattern) were considered for comparison between SCX-fractionated and 
unfractionated samples that were desalted with PGC or C18 SPE columns. 
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Figure 2.3 Analysis of Phosphoserine-containing Phosphopeptides with motif-x 
Phosphorylated peptides from unfractionated samples desalted with PGC and C18 SPE 
columns were analyzed using motif-x. Linear motifs were searched with a minimum number 
of 20 occurrences and a 9 residue window (plus/minus 4 residues from the modified serine) 
with a default value of significance threshold set to 0.000001 searching against the 
International Protein Index human sequence database. The top 8 most abundant motifs are 
listed in descending order based on foreground size (number of phosphopeptides matching 
the motif) with respective fold increase values over the background frequency of serine 
residues.  
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2.2.3 Evaluation of FASP and PP Methods to Prepare Samples for Phosphopeptide 
Enrichment 
 Building on the result that PGC exhibited increased performance in the identification 
of hydrophilic phosphopeptides that conformed to the consensus sequence of CK2, the 
investigation of the utility of two sample preparation methods that are widely used in the 
proteomics field for the preparation of proteomic samples was undertaken (Figure 2.4). This 
comparison was performed in order to determine if proteome sample preparation would 
affect phosphoproteome yield. Filter Aided Sample Preparation (FASP) uses a filtration 
concentrator (in this case with a molecular weight limit of 10,000 Da) to exchange buffers 
during the process of reduction, alkylation and proteolytic digestion. Digested peptides are 
then collected by spinning the concentrator in a centrifuge, resulting in removal of any 
undigested peptides or proteins that are retained by the membrane (102-104). Protein 
precipitation (PP) has been previously used in proteomics to remove non-compatible buffer 
components or detergents from protein extracts prior to proteolytic digestion (105).  This 
strategy has also been adapted with the demonstration of the utility of on-pellet digestion 
using a protease rather than re-suspension in a denaturing solution (106). Our 
phosphopeptide enrichment protocol was also modified to include double incubations with 
TiO2 based on literature reports of increased identification of phosphorylation sites using this 
strategy (107).  Furthermore, we followed the protocol from Kettenbach et al. (108), for 
enrichment from unfractionated samples that employed the use of bulk TiO2 beads as a 
substitute for the enrichment step in a spin-tip format. 
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Figure 2.4 Schematic for Comparative Analysis of FASP and PP Workflows 
(A) Protein lysate from HeLa Tet-Off cells was divided equally into two fractions and 
processed using FASP or PP protocols. Proteome (2) and phosphoproteome (2) samples were 
collected using both workflows and analyzed by LC-MS/MS using a Orbitrap Elite mass 
spectrometer. (B) Overview of samples analysis. Each workflow was performed with 
samples from 3 biological replicates that were each processed and analyzed in technical 
duplicate. All acquired spectra were analyzed in MaxQuant v1.5.3.8. 
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Taken together, the two methods identified a total of 6,153 phosphorylation sites with a 
localization score greater than 0.75 (a maximum score is 1.00), with 63% overlap in terms of 
the sites identified in at least one biological replicate from each of the workflows (Figure 2.5 
A). A phosphorylation site is defined as an identified amino acid residue that is occupied by a 
phosphate and can be identified from multiple phosphopeptides.  Notably, twice as many 
phosphorylation sites were exclusively identified using PP. The number of phosphorylation 
sites identified in all three biological replicates using FASP and PP were 2,511 and 3,111 
respectively (Figure 2.5 B). The percentage of biological replicates where the same site was 
identified in independent LC-MS/MS acquisitions ranged from 41.4 – 48.9% for both 
methods. (Figure 2.5 C). Slightly more than 50% of the identified phosphorylation sites were 
present in all three biological replicates when using each method (Figure 2.5 D). In terms of 
the identification of protein groups using FASP and PP, both methods achieved similar yields 
in terms of the total number of protein groups identified in at least one biological replicate 
(Figure 2.5 A). A protein group is defined as a collection of proteins that cannot be 
individually distinguished based on the identified peptides, such as in the case of protein 
isoforms. Both methods identified slightly over 5,000 protein groups in all three biological 
replicates (Figure 2.5 B). The replicable identification of protein groups was much higher in 
contrast to  phosphorylation site identification, with approximately 90% of protein groups 
being identified in both technical LC-MS/MS analyses (Figure 2.5 C), and approximately 
92% of protein groups identified in all three biological replicates (Figure 2.5 D). In summary, 
the use of protein precipitation in preparing samples for proteomic analysis is advantageous 
given the increased number of phosphorylation sites yielded and the reduction in the number 
of sample handling steps. 
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Figure 2.5 Comparison of FASP and PP Workflows for Phosphoproteomics 
FASP and PP workflows were compared on the basis of identification of phosphorylation 
sites and protein groups. Phosphorylation sites were considered when P localization > 0.75. 
(A) Comparison of sites and protein groups identified in at least one biological replicate. (B) 
Number of sites and protein groups identified in at least one biological replicate and number 
of sites and protein groups identified in all biological replicates. (C) Technical replicability of 
identified sites and protein groups in the same biological replicate. (D) Percentage of 
phosphorylation sites and protein groups that were identified in all three biological replicates.  
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2.3 Discussion 
The specificity determinants of CK2 substrates can render stretches of amino acid 
sequences on a protein hydrophilic (15). In order to implement a phosphoproteomics 
workflow capable of identifying phosphopeptides derived from CK2 substrates, we 
compared solid phase extraction adsorbents for sample preparation and desalting in 
combination with testing SCX-fractionation prior to phosphopeptide enrichment.  
The use of SCX-fractionation appeared to be of limited utility considering the lower yield of 
phosphopeptides identified when either C18 or PGC SPE columns were used for desalting 
steps in comparison to samples that were not fractionated. Furthermore, considering the 
amount of LC-MS/MS time required to analyze 11 SCX fractions (1100 minutes) in 
comparison to 300 minutes for an unfractionated sample, the return on phosphopeptide 
identification with limited sample handling and reduction of desalting steps renders the 
unfractionated “shotgun” approach considerably more advantageous. The requirement for 
desalting after SCX-fractionation may contribute to the lower yield of phosphopeptides. To 
some degree, our results contrast a previous study. In this respect, the utility of SCX-
fractionation has been investigated previously in the application of phosphoproteomics (108) 
where it was demonstrated that fractionation into 24 samples in comparison to an 
unfractionated sample yielded a comparable number of unique phosphorylation sites. In an 
SCX gradient, peptides with lower net charge elute earlier, with multiply-charged species 
eluting later. Multiply-phosphorylated peptides will have a net charge less than zero and will 
elute in the earliest fractions collected. Peptides generated with trypsin will have a net charge 
of +2 at pH 2.7 (in the case of no missed cleavages) when accounting for the N-terminus and 
C terminal arginine or lysine sidechain group, so a singly phosphorylated peptide will have a 
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net charge of +1 (109). SCX fractionation may enable the separation of phosphopeptides 
from non-phosphopeptides but this approach does not drastically outperform the 
unfractionated approach in terms of phosphopeptides identified.  
  The utility of PGC SPE columns in desalting digested peptides was demonstrated in 
the analysis of phosphorylation motifs identified using motif-x from unfractionated samples. 
Although more phosphopeptides were identified using the C18 SPE columns, the 
identification of phosphorylation motifs reminiscent of the specificity determinants of protein 
kinase CK2 from porous graphitic carbon SPE columns was more prevalent when analyzing 
the enrichment of phosphorylation motifs against a background of the human proteome. The 
ability to enrich phosphopeptides matching the specificity determinants of protein kinase 
CK2 using PGC is advantageous. Previous reports using graphite and porous graphitic 
carbon as desalting adsorbents prior to LC-MS/MS analysis have also highlighted the utility 
of this sorbent in phosphoproteomics (98, 99, 110). 
The comparison of FASP and PP as methods to prepare proteomic and 
phosphoproteomic samples for LC-MS/MS analysis highlighted similar yields in protein 
group identification across all biological replicates that were processed.  Furthermore, there 
was similar technical replicability in terms of protein group identification from LC-MS/MS 
run to run. Given that several unique peptides can identify a protein, the identification of 
protein groups using a data-dependent acquisition method does not suffer the same 
constraints that phosphorylation site identification does. Few phosphopeptides can contribute 
to the identification of a phosphorylation site. This is reflective of the stochastic nature of 
data-dependent acquisition and the identification of a labile post-translational modification 
within the constraint of a minimum localization score of 0.75. This issue in data-dependent 
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phosphoproteomics has been identified previously and one alternative to improve future 
analyses within the context of this project would be targeted acquisition of precursor ion 
although this precedes the discovery proteomics stage. Applications of targeted 
phosphoproteomics have increased the identification of phosphosites in technical replicates 
up to 88% (111). Compared to FASP, the protein precipitation (PP) approach yielded 
approximately 24% more phosphosite identifications with the same amount of input material, 
suggesting a better recovery of phosphorylated proteins when precipitating in comparison to 
retention using centrifuge spin concentrators. FASP has been investigated by other groups in 
addition to the development of newer protocols with adjustments made to the types of buffers 
and detergents used for sample processing (112, 113) to increase sample recovery. In 
addition to protocol evolution, the integration of multiple enzyme digestion to generate a 
different pool of peptides has been incorporated (114) and warrants future investigation to 
identify optimal combinations of proteases which would serve in the identification of 
putative CK2 motifs on phosphopeptides.  
The comparative analysis of sample preparation approaches prior to phosphopeptide 
enrichment revealed the advantage of using unfractionated protein samples in addition to the 
use of different adsorbent materials for peptide desalting. Considering the amount of 
instrument time that is logged using a fractionated strategy, the unfractionated approach is 
advantageous in the delivery of LC-MS/MS results in a timely manner. An unfractionated 
approach for phosphoproteome enrichment within this time constraint also enables the 
analysis of more time-points or cellular contexts. Future phosphoproteomic investigations 
will incorporate C18 and porous graphitic carbon in combination with protein precipitation in 
order to identify phosphopeptides conforming to the CK2 consensus sequence by LC-
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MS/MS. In summary, these analyses establish a foundation upon which the development of a 
phosphoproteomic-workflow evolved in order to address the identification of putative CK2 
substrates in future experiments. 
2.4 Experimental Methods 
2.4.1 Cell Culture  
 UTA6 cell line – U2-OS-derived UTA6 cells (a gift from Dr. Christoph Englert, 
Forschungszentrum Karlsruhe, Germany, as previously described in (115)) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 
penicillin (100 U/mL) and streptomycin (100 µg/mL) on 15 cm dishes. Cells were lifted off 
the dish with PBS-EDTA (), centrifuged at 200 x g, rinsed with phosphate-buffered saline 
(PBS), transferred to 1.5 ml micro-centrifuge tubes and snap frozen in liquid nitrogen before 
storage at -80 °C until further use.    
 HeLa Tet-Off cell line – HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10 % FBS, penicillin (100 U/mL) and 
streptomycin (100 µg/mL) on 15 cm dishes.  
2.4.2 Cell Lysis  
 UTA6 cell line – Cell pellets were lysed on ice for 30 minutes with denaturing lysis 
buffer [1% octyl-β-D-glucopyranoside (Sigma-Aldrich), 100 mM ammonium bicarbonate 
(Fluka) pH 8.5, 6 M urea (Sigma-Aldrich), 10% acetonitrile (ACN) (Fisher Scientific), 1 mM 
β-glycerophosphate (Sigma-Aldrich), 1 µM okadaic acid (Bioshop), 25 mM sodium fluoride 
(Sigma-Alrich), 1 µM microcystin-LR (Cayman Chemical), pepstatin (10 µg/mL) (Sigma-
Aldrich)]. Lysates were spun for 10 minutes at 16,000 x g at 4 °C, upon which the 
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supernatant was retained and protein concentration was determined using a Bradford assay 
(Bio-Rad). 
 HeLa Tet-Off cell line – Media was aspirated from culture dishes and cells were 
rinsed with ice cold PBS. Cells were lysed on ice in [1% octyl-β-D-glucopyranoside (Sigma-
Aldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane) (Bioshop) pH 8.5, 6 M urea 
(Sigma-Aldrich), 25 mM β-glycerophosphate (check), 1 µM okadaic acid (Bioshop), 50 mM 
sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR (Cayman Chemical), 10 mM sodium 
orthovanadate (Aldrich), 5 mM sodium pyrophosphate (Sigma-Aldrich), pepstatin (10 
µg/mL) (Sigma-Aldrich)]. Samples were sonicated 2 x 15 seconds on ice then spun for 10 
minutes at 16,000 x g at 4 °C, upon which the supernatant was retained and protein 
concentration was determined using a Bradford assay (Bio-Rad). 
2.4.3 Sample Preparation for Comparison of Unfractionated vs. Strong Cation 
Exchange-Fractionated Phosphoproteome of UTA6  Cells 
Protein lysate from UTA6 cells (a total of 20 mg) was divided into microfuge tubes in 2.5 mg 
aliquots and processed for in-solution digestion. Samples were reduced with 10 mM DTT 
(Sigma Aldrich) for 45 minutes at room temperature and then alkylated with 40 mM 
iodoacetamide (IAA) (Sigma Aldrich) in the dark for 45 minutes at room temperature, 
followed by quenching the reaction with the addition of 10 mM DTT for 45 minutes at room 
temperature. Samples were then diluted 1:4 using 50 mM ammonium bicarbonate pH 8.5 
(ABC) and digested overnight for 18 hours at 37 °C with trypsin (Pierce) at a ratio of 1:100 
(w/w). The next morning the reaction was stopped by the addition of 10% formic acid (FA). 
Peptides were desalted by solid phase extraction (SPE) using porous graphitic carbon (PGC) 
(HyperSep Hypercarb, Thermo Scientific) and C18 (Strata, Phenomenex) columns. PGC 
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columns were activated with 3 x 1 mL of 70% (v/v) ACN, 0.1% (v/v) FA, followed by 3 x 1 
mL with 0.1% (v/v) FA. 10 mg of digested peptides were loaded on each column followed by 
washing with 3 x 1 mL of 0.1% (v/v) FA and eluted using 1 mL 70% (v/v) ACN, 0.1% (v/v) 
FA. C18 columns were activated with 3 x 1 mL of 0.1% FA (v/v) in ACN, followed by 3 x 1 
mL of 0.1% (v/v) FA. 10 mg of digested peptides were loaded on columns followed by 3 x 1 
mL of 0.1% (v/v) FA and eluted using 1 mL 50% (v/v) ACN, 0.1% (v/v) FA. Samples were 
then concentrated in a vacuum centrifuge until near-dryness and reconstituted in 0.1% (v/v) 
FA. 75% of the sample was designated for fractionation by strong cation exchange (SCX) 
chromatography with 25% of the sample designated for immediate phosphopeptide 
enrichment. 
2.4.4 Offline Fractionation of Digested UTA6 Peptides Using Strong Cation Exchange 
Chromatography 
 Peptides desalted by C18 and PGC SPE columns were reconstituted in 100 µL of 0.1 
FA and fractionated offline in SCX mode using a poly(2-sulfoethyl aspartamide) column 
(100 x 4.6 mm, 5 µm, 200 Å) (PolySULFOETHYL A, PolyLC Inc.) connected to an Agilent 
1100 HPLC with quaternary pump at a flowrate of 1.5 mL/min, monitoring absorbance at 
220 nm. Mobile phase A consisted of 10 mM KH2PO4 pH 2.7, 20% ACN (v/v) and mobile 
phase B consisted of 10 mM KH2PO4 pH 2.7, 500 mM KCl, 20% ACN (v/v). Fractionation 
was performed using an 85 minute method consisting of a linear gradient as follows: 0% B 
from 0 to 13 minutes, 25% B from 14 to 43 minutes, 100% B from 44 to 53 minutes, 100% B 
from 53 to 60 minutes, with fractions collected every minute. Samples that were initially 
desalted by PGC and C18 prior to SCX fractionation were again desalted by the respective 
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SPE column after pooling both sets of respective samples into 11 fractions based on 
absorbance at wavelength 220 nm. 
2.4.5 Phosphopeptide Enrichment of UTA6 SCX-Fractionated and Unfractionated 
Peptides 
 SCX-fractionated and unfractionated peptides prepared from UTA6 cell lysate were 
enriched for phosphopeptides using a TiO2 phosphopeptide enrichment kit (Cat #88301, 
Pierce) following the manufacturer’s instructions.  
2.4.6 Filter Aided Sample Preparation (FASP) of HeLa Tet-Off lysates  
Protein lysate (2 mg) from each biological replicate was reduced with 5 mM DTT for 
30 minutes at room temperature. Centrifugal filter units with 10 kDa – cutoff membranes 
(Amicon Ultra 15 mL, Millipore) were conditioned with 50 mM Tris pH 8.5, 8 M urea as per 
the manufacturer’s instructions. Samples were then added to centrifugal filter units and 
mixed with 4 mL of 50 mM Tris pH 8.5, 8 M urea and spun at 4, 925 x g for 15 minutes at 
room temperature, repeating the addition of 4 mL 50 mM Tris pH 8.5, 8 M urea and 
centrifugation. Samples were then alkylated with 10 mM IAA for 20 minutes in the dark, 
followed by the addition of 4 mL 50 mM Tris pH 8.5, 8 M and centrifugation which was 
repeated twice. The concentration of urea was then diluted by the addition of 4 mL 100 mM 
Tris pH 8.5 and centrifugation, which was repeated twice. After the final dilution step trypsin 
(Pierce) was added at a ratio of 1:100 (w/w) and samples were digested overnight for 18 
hours at 37 °C. Samples were then added to new centrifugal filter units with 10 kDa – cutoff 
(Amicon Ultra 0.5 mL, Millipore) which had been previously conditioned with 100 mM Tris, 
pH 8.5 as per the manufacturer’s instructions. Samples were then spun at 14,000 x g until all 
of the filtrate was collected, and acidified with 10% FA. An aliquot was desalted by C18 
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StageTips (116), with the remainder of the digested peptides were desalted using C18 SPE 
columns, from which the flow-through and wash fractions were retained and desalted on 
PGC SPE columns. Samples were then concentrated in a vacuum centrifuge until near-
dryness and reconstituted in 0.1% (v/v) FA. 
2.4.7 Protein Precipitation and On-Pellet Digestion (PP) of HeLa Tet-Off Lysates 
 Protein lysate (2 mg) from each biological replicate was precipitated by the addition 
of 6 sample volumes of 10% trichloroacetic acid (TCA) (v/v) (BDH Chemicals) in acetone 
(EMD Millipore) at – 20 °C overnight. Samples were spun at 16,000 x g for 10 min at 4 °C 
to pellet precipitated protein, followed by removal of supernatant using vacuum aspiration, 
and ice-cold acetone was added to wash the pellet, followed by centrifugation and a 
subsequent wash step. Protein pellets were reconstituted in twice the original lysate sample 
volume in 50 mM Tris-HCl pH 8.5, 0.02% ProteaseMAX (Promega) with 1:100 trypsin 
(w/w) and digested for 4 hours at 37 °C with agitation in a shaking incubator. Samples were 
then reduced with 5 mM DTT for 30 minutes, followed by alkylation with IAA for 20 
minutes in the dark. Alkylation was quenched with 5 mM DTT for 30 minutes, and an 
additional aliquot of 1:100 trypsin was added to samples before samples were incubated 
overnight for 18 hours at 37 °C with agitation. The next day samples were acidified with 
10% FA, spun at 3,000 x g to remove insoluble debris, after which a small aliquot was 
desalted by C18 StageTips (116), while the remainder of the digested peptides were desalted 
using C18 SPE columns, from which the flow-through and wash fractions were retained and 
desalted on PGC SPE columns. Samples were then concentrated in a vacuum centrifuge until 
near-dryness and reconstituted in 0.1% (v/v) FA. 
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2.4.8 Phosphopeptide Enrichment of FASP and PP Digested Peptides 
 Reconstituted peptides desalted by C18 and PGC columns were measured using A280 
absorbance on a Nanodrop (Thermo Scientific) to estimate peptide yield and combined. 
Samples were adjusted to 2 M lactic acid (Sigma-Aldrich), 50% ACN (v/v) and mixed. Bulk 
10 µM titanium dioxide (TiO2) beads (5020-75010, GL Sciences) previously washed and 
incubated in 2 M lactic acid, 50% ACN (v/v) (binding buffer) were added to peptides at a 
ratio of 4:1 (w/w) (400 µg of TiO2 beads per 100 µg of peptides) in micro-centrifuge tubes 
and incubated for 30 minutes at room temperature with end-over-end rotation. Samples were 
then spun at 8,000 x g for 1 minute, after which the supernatant was removed and transferred 
to a new tube for a second incubation with TiO2 beads. After a second incubation with TiO2 
beads for 30 minutes, the supernatant was retained, vacuum centrifuged, and desalted using 
C18 micro-columns (C18 StageTips) (116). TiO2 beads were then washed twice by adding 
500 µL of binding buffer and mixing vigorously using a vortex genie, followed by 
centrifugation at 8,000 x g for 1 minute. TiO2 beads were then reconstituted in 500 µL of 
50% ACN (v/v) and transferred to new micro-centrifuge tubes, followed by centrifugation at 
8,000 x g for 1 minute, vacuum aspiration of supernatant and washed with 500 µL of 50% 
ACN (v/v). This wash process was repeated for a total of three times. Phosphopeptides bound 
to the TiO2 beads were eluted with two volumes of 300 µL of 5% NH4OH (v/v) (Fluka), 50% 
ACN (v/v) (elution buffer) using centrifugation to pellet the beads in order to remove the 
eluate. The eluate was passed through a StageTip containing one layer of C18 material by 
centrifugation at 3000 x g for 2 minutes to retain any TiO2 beads, followed by the addition of 
100 µL of 80% ACN (v/v). Filtered eluate was concentrated using vacuum centrifugation 
until near dryness and reconstituted in 1% FA.  
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2.4.9 LC-MS/MS Data Acquisition of UTA6 SCX-Fractionated and Unfractionated 
Phosphopeptides 
 Samples were injected using a NanoAcquity UPLC (Waters) onto a Symmetry C18 
trapping column (20 mm x 180 µm i.d., 5 µm, 100 Å) at a flow rate of 10 µL/min in 99% 
mobile phase A (0.1% FA (v/v), 1% mobile phase B (0.1% FA (v/v) in ACN) for 4 minutes. 
Samples were then separated on a NanoAcquity Peptide BEH C18 analytical column (250 
mm x 75 µm i.d., 1.7 µm, 130 Å) at a flow rate of 300 nL/min by a linear gradient of 
increasing mobile phase B. Fractionated samples were separated using a gradient from 7.5% 
to 37.5% mobile phase B over 60 minutes (total run time 100 minutes per sample) and 
unfractionated samples were separated using a gradient from 5% to 37.5% mobile phase B 
over 240 minutes (total run time 300 minutes per sample). Separated peptides were ionized 
using a nano-Electro Spray Ionization source connected to the analytical column by a fused-
silica capillary emitter (New Objective). Ionized peptides were analyzed using a QExactive 
Hybrid Quadrupole-Orbitrap mass spectrometer (Thermo Scientific) operated by Thermo 
XCalibur (software version 2.2.1.1646) in data-dependent mode. Full MS1 scans were 
performed at 70,000 resolution, scanning from 400 – 1800 m/z with AGC set to 1 x 106 ions 
and an isolation window of 4.0 m/z. The top 12 most abundant ions were selected for MS2 
for SCX-fractionated samples and the top 24 most abundant ions were selected for MS2 for 
unfractionated samples. A lock mass ion was enabled for 445.120025 m/z (117). Maximal 
injections times for MS1 acquisition was 120 ms and 30 ms for SCX-fractionated and 
unfractionated samples, respectively. Peptide ions were fragmented using HCD with NCE set 
to 23% and data-dependent MS2 scans were performed at 17,000 resolution with a dynamic 
  
44 
exclusion window of 60 seconds. Maximal injection times for MS2 acquisition was 120 ms 
and 100 ms for SCX-fractionated and unfractionated samples, respectively.  
2.4.10 LC-MS/MS Data Acquisition of HeLa Tet-Off FASP and PP Phosphopeptides 
Samples were injected using a NanoAcquity UPLC (Waters) onto a Symmetry C18 
trapping column (20 mm x 180 µm i.d., 5 µm, 100 Å) at a flow rate of 10 µL/min in 99% 
mobile phase A (0.1% FA (v/v), 1% mobile phase B (0.1% FA (v/v) in ACN) for 4 minutes. 
Samples were then separated on a NanoAcquity Peptide BEH C18 analytical column (250 
mm x 75 µm i.d., 1.7 µm, 130 Å) at a flow rate of 300 nL/min by a linear gradient of 
increasing mobile phase B from starting condition 7.5% to 25% for 180 minutes, followed by 
25% to  32.5% for 40 minutes, and culminating at 60% at 240 minutes. Separated peptides 
were ionized using a nano-Electro Spray Ionization source connected to the analytical 
column by a fused-silica capillary emitter (New Objective). Ionized peptides were analyzed 
using a Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer (Thermo Scientific) 
operated by Thermo XCalibur (software version 2.7.0.1094) in data-dependent mode. Full 
MS1 scans were performed at 120,000 resolution, scanning from 400 – 1450 m/z with AGC 
set to 5 x 102 ions and an isolation window of 1.0 m/z. The top 20 most abundant ions were 
selected for MS2. A lock mass ion was enabled for 445.120025 m/z (117). Maximal injection 
time for MS1 acquisition was 200 ms and 50 ms for MS2. Peptide ions were fragmented 
using CID with NCE set to 35% with activation time set to 10 ms and a Q value of 0.25. 
Data-dependent MS2 scans were acquired in the linear ion trap using rapid scan selection, 
with a dynamic exclusion window of 60 seconds. 
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2.4.11 Data Analysis of UTA6 SCX-Fractionated and Unfractionated Phosphopeptides 
 Raw mass spectra were analyzed in PEAKS version 7.0 (Bioinformatics Solutions 
Inc.) (118, 119). Once loaded in PEAKS, mass spectra were refined and analyzed by de novo 
sequencing with the following parameters; parent mass error tolerance 20.0 ppm, fragment 
mass error tolerance 0.02 Da, enzyme specificity trypsin, fixed modification cysteine 
carbamidomethylation (+ 57.0215), variable modifications methionine oxidation (+15.9949), 
asparagine and glutamine deamidation (+0.9840 Da), serine and threonine phosphorylation 
(+79.9663). The maximum number of variable modifications was set to 4. Following de novo 
sequencing, data were searched against the UniProt sequence database (homo sapiens taxon, 
accessed on March 11, 2014) using the same parameter constraints as de novo sequencing in 
addition to 3 maximum missed cleavages for sequence matching. Peptide spectrum matches 
were restricted to a 1% false discovery rate (FDR) threshold against a target-based decoy 
database. Identified phosphopeptides were compared amongst the four datasets (SCX-
fractionated and unfractionated samples desalted by PGC or C18) for shared or 
complementary sets of phosphopeptides. Using motif-x (100, 101), identified peptide 
sequences from PGC and C18 unfractionated samples that were exported from PEAKS were 
searched for statistically over-represented linear motifs centered on phosphorylated serine 
residues against the human proteome fasta sequence database of the International Protein 
Index built into motif-x. Linear motifs were considered with a minimum number of 20 
occurrences and a 9 residue window (plus/minus 4 residues from the modified serine) with a 
default value of significance threshold set to 0.000001.  
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2.4.12 Data Analysis of HeLa Tet-Off FASP and PP Phosphopeptides 
 Raw mass spectra files were analyzed in MaxQuant version 1.5.3.8 (70, 71, 120) and 
searched against the Uniprot sequence database (homo sapiens taxon, accessed on June 10, 
2015). Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the 
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7, 
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease 
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The option 
for second peptide search was selected, as was the use of “Match Between Runs” for 
respective pairs of samples between biological replicates, using the default matching 
parameters. A maximum number of variable modifications per peptide was 5, with 
methionine oxidation (+15.9949), asparagine and glutamine deamidation (+0.9840 Da), and 
serine and threonine phosphorylation (+79.9663) selected. Cysteine carbamidomethylation (+ 
57.0215) was set as a fixed modification. Raw mass spectra files were defined as separate 
groups using the experimental setup option. The minimum score for modified peptides was 
set to 40, and the decoy-database setting was “Revert.” Output data from MaxQuant was then 
loaded into Perseus version 1.5.2.6 (121). For the comparison of proteome data between 
FASP and PP, the “proteinGroups.txt” file was first removed of entries marked as reverse 
decoy database hits, contaminants, and protein identifications that were only matched to 
modified peptides. Proteins were considered identified in each biological replicate if 
identified in at least one of two technical replicates. For the comparison of the 
phosphoproteome data between FASP and PP, the “Phospho (ST)Sites.txt” file was removed 
of entries marked as reverse decoy database hits and filtered to only contain phosphorylation 
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sites with localization probability greater than 0.75. Phosphosites were considered identified 
in each biological replicate if identified in at least one of two technical replicates. 
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2.5 Supplemental 
 
 
 
Supplemental Figure 2.1 Companion to Figure 2.2 
Chromatograms for SCX separation of peptides desalted using PGC (top) and C18 (bottom.) 
Peptides were separated at a flow-rate of 1.5 mL/min, monitoring absorbance at 220 nm. 
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3 Chapter 3 – Investigation of the Phosphoproteome in Response to CX-4945 
Treatment 
3.1 Introduction 
It is estimated that potentially 700,000 phosphorylation sites may exist in the human 
proteome (6). Furthermore, current “deep” proteomic profiling methods can identify up to 
50,000 phosphorylation sites in human cells, representing three quarters of the proteins that 
are detectable by mass spectrometry (7). The regulation of phosphorylation is a central 
component in maintaining cellular homeostasis and is regulated by protein kinases which 
catalyze the transfer of phosphate from ATP to serine, threonine or tyrosine residues (122). 
Not surprisingly, these enzymes have quickly emerged as potential therapeutic targets of 
interest for the treatment of a number of human diseases (9). Protein kinase CK2 has 
attracted interest as a potential therapeutic target since it has been identified as a kinase that 
is expressed at high levels in different types of human cancers (16). A recent report has also 
noted that de-regulation of expression exists at the transcript level for the catalytic and 
regulatory subunits of CK2 (14). The first orally-bioavailable inhibitor of CK2, CX-4945 
(44), recently entered clinical trial for the treatment of cholangiocarcinoma in combination 
with gemcitabine and cisplatin, and is touted as a highly selective and specific inhibitor of 
CK2 (123). CX-4945 has been used extensively in the literature in different models of 
multiple myeloma, lymphoma, and leukemia (50, 53, 54, 124, 125), and these studies have 
implicated CK2 activity in the regulation of different pathways. Characterization of the 
impact of CX-4945 on a cellular phosphoproteome would enable a better understanding of 
the processes and pathways that that enable cell death via CK2 inhibition. Additionally, it 
would allow for an unbiased assessment of the potential for the regulation of other kinases 
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considering this inhibitor is ATP-competitive. To date, proteomics strategies have not been 
applied for characterizing the phosphoproteome of cells treated with CX-4945, and the most 
recent studies with an inhibitor of CK2, quinalizarin, have not capitalized on translational 
capacity due to its limited clinical utility (126, 127).  
In this chapter the phosphoproteomics workflow that was optimized previously in 
Chapter 2 is used to perform unbiased quantitative phosphoproteomic profiling of HeLa cells 
treated with CX-4945 within a window of 240 minutes. SILAC (Stable Isotopic Labeling of 
Amino Acids in Cell Culture) was utilized in order to perform relative quantification of the 
phosphoproteome and proteome. To identify phosphorylated substrates that could serve as 
dynamic markers of CK2 activity, a bioinformatics approach was undertaken and a kinase-
substrate prediction tool, KinomeXplorer (77) was utilized. In order to gauge the impact of 
CX-4945 treatment on the phosphoproteome and to identify kinases-substrate relationships 
that were perturbed in response to CX-4945 treatment, the PHOXTRACK tool (128) was 
also employed. A global assessment of the biological processes and pathways with 
phosphorylation sites perturbed by CX-4945 was performed using gene enrichment analysis 
with g:Profiler (129). Collectively, these analyses reveal a broad impact of CX-4945 on 
several different processes and distinct areas of regulation.  
3.2 Results  
3.2.1 Evaluation of CK2 Inhibition Using a Bona-Fide Substrate EIF2S2 
A previous study by Geiger et al. identified that amongst 11 commonly used cell line 
models there is ubiquitous expression of proteomes (130). Taking into consideration the 
availability of existing cell line models in our laboratory and the use of a commercially 
available HeLa proteome standard for LC-MS/MS analysis, we performed experiments in the 
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HeLa cell line. Prior to embarking on a quantitative phosphoproteomic analysis of CX-4945 
in HeLa cells, we adapted the cell line in SILAC medium for a period of 7 days and 3 sub-
passages to ensure that proteins were isotopically-labeled to greater than 95% as is routinely 
performed (69). We used medium containing proline to prevent arginine-to-proline 
conversion (131). Heavy labeled samples were digested and raw spectra acquired by LC-
MS/MS, followed by analysis in MaxQuant to assess the extent of isotopic labeling of 
proteins (70, 71, 120). The median incorporation efficiency was over 96% (Supplemental 
Figure 3.13.1) and the distribution of incorporation amongst all peptides detected and 
quantified was skewed towards 100% incorporation. Following confirmation of successful 
incorporation of isotopically-labelled amino acids, a time-course experiment was performed 
using CX-4945 at 20 µM up to 24 hours of treatment in HeLa cells to identify a window of 
time in which inhibition of CK2 would precede secondary signaling events such as DNA 
damage or apoptosis, given that CK2 has previously been demonstrated to regulate the 
phosphorylation of constituents of the DNA damage and repair pathways (29, 37, 132, 133) 
and implicated in the regulation of apoptotic pathways (27, 34). Confirmation of CK2 
inhibition was based upon the phosphorylation status of a well-characterized bona fide 
substrate, EIF2S2 (11, 134), for which a phospho-specific antibody was raised in our 
laboratory. Western blotting with antibodies directed against phospho-EIF2S2 Ser2, PARP, 
and γH2AX Ser139 identified a period of time up to 4 hours in which the lysates derived 
from CX-4945 treated samples were comparable to an untreated sample in terms of 
appearance of cleaved PARP and γH2AX Ser139 (Supplemental Figure 3.23.2), suggesting 
that within this window of time the inhibition of CK2 preceded the activation of other 
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signaling pathways which could interfere with the interpretation of events succeeding CK2 
inhibition.  
3.2.2 Unbiased Phosphoproteomic Evaluation of HeLa Cells Treated with CX-4945 
Following confirmation of CK2 inhibition using anti-phospho-EIF2S Ser2 antibody to probe 
unlabeled lysates derived from HeLa cells treated with CX-4945, SILAC labeled HeLa cells 
were treated with 20 µM CX-4945 or with DMSO for periods of 60, 135, 180 and 240 
minutes. These samples were separated by SDS-PAGE, transferred to membrane and probed 
using antibodies against phospho-EIF2S2 Ser2, PARP, phospho-ATM Ser1981, and γH2AX 
Ser139 (Supplemental Figure 3.33.3-3.5). Western blotting confirmed that over the time-
course of 240 minutes, the inhibition of CK2 using CX-4945 was apparent with the decrease 
in phospho-EIF2S2 Ser2 signal. During the period in which CX-4945 treatment occurred, 
CK2 inhibition was not secondary to events such as the activation of apoptosis or the 
activation of DNA-damage. These processes would be apparent with the cleavage of PARP 
or increase of γH2AX Ser139 respectively. By comparison, lysates derived from cells treated 
with a promiscuous kinase inhibitor such as staurosporine or a chemical which induces DNA 
damage such as neocarzinostatin, displayed activation of apoptosis and evidence of DNA 
damage. Next, equal amounts of light and heavy lysates were combined and digested with 
trypsin and Lys-C proteases, followed by desalting and phosphopeptide enrichment. 
Proteome samples were retained as well. By combining samples prior to processing and 
enrichment, bias in phosphopeptide abundance between a treated and a control sample was 
eliminated. Quantitative analysis by mass spectrometry enables the MS1 peptide features to 
be utilized to measure the difference in abundance between SILAC pairs of peptides, and the 
MS2 spectrum confirms peptide sequence identity and phosphorylation site localization 
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(Figure 3.1). In total, 48 fractions derived from four time-point datasets of three biological 
replicates were analyzed by LC-MS/MS in technical duplicate (Figure 3.2 A). This resulted 
in the identification and quantification of 3,003 phosphorylation sites and 2,805 protein 
groups in three out of three biological replicates across all time-points that were profiled 
(Figure 3.2 B, C, D). Phosphorylation sites were categorized on the magnitude of change and 
whether the change was statistically significant based on a one-sample Student’s t test with 
Benjamini Hochberg FDR of 0.05 for multiple hypothesis correction (Figure 3.2 C and 
Supplemental Figure 3.63.6-3.9). Of these, sites which are predicted to be phosphorylated by 
CK2 as identified using KinomeXplorer (77) constitute a small number of the sites that 
decrease greater than log2 -1 (a two-fold change). To note, the magnitude of change in 
phosphorylation of TOP2A at Ser1377, a well-characterized CK2 substrate (135), is 
substantially greater when compared to EIF2S2 Ser2 at 60 minutes of CX-4945 treatment 
and over the period of inhibitor treatment up to 240 minutes (Figure 3.3). Other 
phosphorylation sites from bona fide CK2 substrates within this period of treatment do not 
show as dynamic de-phosphorylation. This suggests preferential activity of phosphatases 
directed towards sites of phosphorylation by CK2. The broader impact on the 
phosphoproteome can be visualized using volcano plots (Figure 3.4-3.7), where it is evident 
based on the distribution of phosphorylation sites that increase and decrease upon treatment 
that CX-4945 elicits a dynamic phosphoproteome.  
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3.2.3 Dynamic Phosphorylation is Independent of Protein Abundance 
In parallel with phosphopeptide analysis to investigate the phosphoproteome of HeLa 
cells perturbed with CX-4945, proteomic samples were analyzed by LC-MS/MS as well to 
quantify the proteome. When surveying the distribution of quantified proteins in each 
particular time-point, the distribution of quantified protein group ratios falls within log2 -/+ 
0.5, suggesting that the proteome in general does not change in cells that are treated with CX-
4945 up to a period of 240 minutes (Supplemental Figure 3.10-3.13). Additionally, those 
phosphorylation sites that were categorized as statistically significant were plotted against the 
corresponding protein ratio (Figure 3.8-11) for each individual time-point dataset to confirm 
that the change in the phosphoproteome is independent of protein abundance. 
Phosphorylation sites identified as CK2 substrates showed dramatic decrease in 
phosphorylation upon CX-4945 treatment and this was not due changes in protein 
abundance. 
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Figure 3.1 Phosphoproteomics Workflow to Investigate CX-4945 in HeLa Cells. 
HeLa cells were adapted in SILAC media and treated with CX-4945 for a period up to 240 
minutes. Lysates were mixed 1:1 and digested with trypsin and Lys-C, followed by 
phosphopeptide enrichment and analysis by LC-MS/MS. Relative quantitation was 
performed on raw mass spectra using MaxQuant and identified and quantified sites were 
analyzed using bioinformatics tools to investigate kinase-substrate relationships.  
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Figure 3.2 Experimental Layout and Data Summary 
(A) Processing of treated and control samples for LC-MS/MS analysis resulted in four 
fractions per biological replicate which were analyzed in technical duplicate. (B) Summary 
of total number of spectra acquired. (C) Number of phosphorylation sites identified and 
quantified in 3/3 biological replicates and number that changed in response to CX-4945 that 
met significance criteria. (D) Number of protein groups identified in 3/3 biological replicates.  
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Figure 3.3 Phosphorylation Dynamics of Identified CK2 Sites Using KinomeXplorer. 
Subset of phosphorylation sites identified as CK2 substrates that were quantified in all 
biological replicates and time-points. In each panel header a concatenated identifier 
consisting of the protein Uniprot accession code, amino acid residue, sequence position of 
the phosphorylation site and multiplicity is shown. Error bars denote standard deviation of all 
three biological replicates quantified.  
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Figure 3.4 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated 
with 20 µM CX-4945 for 60 Minutes. 
Quantified phosphorylation sites were tested for significance using a one-sample Student’s t-
test with FDR correction (<0.05). Points in grey exceed statistical significance cut-off. CK2 
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites 
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs; 
horizontal line denotes FDR threshold of P < 0.05. 
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Figure 3.5 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated 
with 20 µM CX-4945 for 135 Minutes. 
Quantified phosphorylation sites were tested for significance using a one-sample Student’s t-
test with FDR correction (< 0.05). Points in grey exceed statistical significant cut-off. CK2 
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites 
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs; 
horizontal line denotes FDR threshold of P < 0.05. 
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Figure 3.6 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated 
with 20 µM CX-4945 for 180 Minutes. 
Quantified phosphorylation sites were tested for significance using a one-sample Student’s t-
test with FDR correction (< 0.05). Points in grey exceed statistical significance cut-off.  CK2 
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites 
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs; 
horizontal line denotes FDR threshold of P < 0.05. 
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Figure 3.7 Volcano Plot of Quantified Phosphorylation Sites from HeLa Cells Treated 
with 20 µM CX-4945 for 240 Minutes. 
Quantified phosphorylation sites were tested for significance using a one-sample Student’s t-
test with FDR correction (< 0.05). Points in grey exceed statistical significance cut-off.  CK2 
phosphorylation sites identified by KinomeXplorer are highlighted in orange. Labeled sites 
exceed log2 -1 and are significant. Vertical dashed lines denote -1 and +1 Log2 cutoffs; 
horizontal line denotes FDR threshold of P < 0.05. 
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Figure 3.8 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells 
Treated with 20 µM CX-4945 for 60 Minutes. 
Phosphorylation sites that were statistically significant were plotted against the respective 
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean 
Log2 ratio for the respective protein abundance, all derived from three biological replicates. 
CK2 phosphorylation sites are highlighted in orange. Labeled sites exceed Log2 -1. 
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Figure 3.9 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells 
Treated with 20 µM CX-4945 for 135 Minutes. 
Phosphorylation sites that were statistically significant were plotted against the respecrive 
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean 
Log2 ratio for the respective protein abundance, all derived from three biological replicates. 
CK2 phosphorylation sites are highlighted in orange.  Labeled sites exceed Log2 -1. 
 
  
  
64 
 
Figure 3.10 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells 
Treated with 20 µM CX-4945 for 180 Minutes. 
Phosphorylation sites that were statistically significant were plotted against the respective 
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean 
Log2 ratio for the respective protein abundance, all derived from three biological replicates. 
CK2 phosphorylation sites are highlighted in orange.  Labeled sites exceed Log2 -1. 
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Figure 3.11 Comparison of Phosphorylation Site vs. Protein Abundance in HeLa Cells 
Treated with 20 µM CX-4945 for 240 Minutes. 
Phosphorylation sites that were statistically significant were plotted against the respective 
protein ratio. Displayed are the mean Log2 ratios for a phosphorylation site and the mean 
Log2 ratio for the respective protein abundance, all derived from three biological replicates. 
CK2 phosphorylation sites are highlighted in orange.  Labeled sites exceed Log2 -1. 
 
  
  
66 
3.2.4 CX-4945 Treatment Affects Phosphorylation Mediated by Kinases Other Than 
CK2  
CK2 can regulate the activity of other kinases by phosphorylation of cdc37 Ser13 
(136), which is a kinase-chaperone that can regulate client kinases concurrently with Hsp90 
(137). CX-4945 itself is a small molecule ATP-competitive inhibitor, and could target other 
kinases other than CK2 in the cell. Considering these points, kinase-substrate enrichment 
analysis was performed using PHOXTRACK (128) to investigate the impact of CX-4945 
treatment. This analysis was performed using information found in PhosphoSitePlus and the 
kinase-substrate relationships that are listed (138). Phosphorylation sites quantified in each 
time-point dataset were analyzed separately and Kolmogorov-Smirnov unweighted running 
sum statistics were calculated. PHOXTRACK scores for a particular kinase reflect the 
enrichment value as computed by running sum statistics for the set of phosphorylation sites 
that are attributed to a particular kinases and are adjusted using the false-discovery rate 
(FDR). Activation or inhibition of a particular kinase can be inferred by the trend of 
attributed phosphorylation sites; whether these sites are trending as increased in 
phosphorylation or decreased in phosphorylation. Analysis using PHOXTRACK revealed 
kinases (FDR < 0.25) that were inhibited or activated as inferred by the quantification of 
attributed phosphorylation sites in PhosphoSitePlus for the four time-point datasets (Figure 
3.12). Interestingly, at 60 minutes of CX-4945 treatment, mTOR and Akt are down-regulated 
with CDK1, CDK2 and LATS1 being up-regulated. The phosphorylation of several CK2 
substrates suggests that there is inhibition of CK2 although the bioinformatics analysis 
derived from information attributed in PhosphoSitePlus does not meet the FDR cut-off of 
0.25. Notably, in agreement with previous analysis using KinomeXplorer, there are  
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Figure 3.12 PHOXTRACK Analysis of Phosphorylation Sites Quantified at Each Time-
Point. 
Phosphorylation sites were analyzed using PHOXTRACK which uses Kolmogorov-Smirnov 
unweighted running sum statistics to calculate activation or inhibition of a kinase based on 
the assigned substrates in PhosphoSitePlus database . Shown are heat maps with kinases that 
exceeded a FDR threshold of < 0.25 in each time-point. 
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Figure 3.13 Quantified CK2 Phosphorylation Sites in PhosphoSitePlus from HeLa Cells 
Treated with 20 µM CX-4945. 
Phosphorylation sites listed as CK2 substrates in PhosphoSitePlus database are presented. 
The mean log2 ratio from three biological replicates is used to calculate the change 
represented by each bar for a given phosphorylation site.  
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Figure 3.14 Quantified mTOR Phosphorylation Sites In PhosphoSitePlus from HeLa 
Cells Treated with 20 µM CX-4945. 
Phosphorylation sites listed as mTOR substrates in PhosphoSitePlus database are presented. 
The mean log2 ratio from three biological replicates is used to calculate the change 
represented by each bar for a given phosphorylation site. 
 
  
  
70 
 
Figure 3.15 Quantified Akt Phosphorylation Sites in PhosphoSitePlus from HeLa Cells 
Treated with 20 µM CX-4945. 
Phosphorylation sites listed as CK2 substrates in PhosphoSitePlus database are presented. 
The mean log2 ratio from three biological replicates is used to calculate the change 
represented by each bar for a given phosphorylation site. 
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substrates of CK2 that decrease in response to CX-4945 (Figure 3.13). Substrates of the 
mTOR and Akt kinases also decreased in phosphorylation (Figure 3.14-3.15) including 
EIF4EBP1 Thr46/Ser65/Thr70 and AKT1S1 Thr246, suggesting that CX-4945 down-
regulates the mTOR/Akt pathways, although at this point it is unclear whether this is the 
result of a CK2-dependent or independent inhibition.  
3.2.5 CX-4945 Impacts Distinct Biological Processes and Pathways in HeLa Cells 
To investigate the biological processes and pathways that could be affected by CX-4945 
treatment, gene enrichment analysis was performed using g:Profiler (129) and gene ontology 
(GO) terms for biological processes (139), KEGG pathways (140), and Reactome pathways 
(141) were queried. Statistically significant phosphorylation sites across the four time-point 
datasets were pooled into three groups: those with quantified ratios less than log2 -1 (i.e. a 
reduction in phosphorylation by more than 50%), greater than log2 +1 (increase in 
phosphorylation by two-fold) and those sites that were identified as CK2 substrates which 
decreased greater than log2 -1. Enriched terms were visualized using Cytoscape and the 
EnrichmentMap plugin (Figure 3.16-3.17 – and Supplemental Figure 3.14-3.15)(142). 
Processes that were identified from phosphorylation sites that decreased in response to CX-
4945 treatment are involved in mTOR signaling, ribosome biogenesis, RNA splicing, 
cytoskeletal organization, chromosome condensation and nuclear envelope assembly (Figure 
3.16 A). Processes that were identified from CK2 substrates were involved in DNA repair 
and translation (Figure 3.16 B). Processes that were identified from phosphorylation sites that 
increased in response to CX-4945 are involved in nuclear transport, RNA splicing, negative 
cell cycle regulation,  
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Figure 3.16 EnrichmentMap Network of Biological Processes Enriched from 
Decreasing Quantified Phosphorylation Sites Using g:Profiler. 
Phosphorylation sites that decreased across all time-points greater than log2 -1 were used for 
gene enrichment using g:Profiler. Networks were constructed in Cytoscape with a similarity 
score cut-off of 0.5 and a FDR q value of 0.005. Nodes represent GO pathways, processes 
and functions and are connected by edges where edge thickness corresponds to the number of 
genes shared between two different nodes. Labels and font size correspond with 
overrepresented terms. (A) Phosphorylation sites that decreased in response to CX-4945. (B) 
Phosphorylation sites identified as CK2 using KinomeXplorer. 
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Figure 3.17 EnrichmentMap Network of Biological Processes Enriched from Increasing 
Quantified Phosphorylation Sites Using g:Profiler. 
Phosphorylation sites that increased across all time-points greater than log2 +1 were used for 
gene enrichment using g:Profiler. Networks were constructed in Cytoscape with a similarity 
score cut-off of 0.5 and a FDR q value of 0.005. Labels and font size correspond with 
overrepresented terms. 
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apoptotic execution and microtubule regulation (Figure 3.17). The topology of the biological 
processes and pathways that are affected by CX-4945 suggests a broad network that could be 
regulated by CK2, however complementary sets within phosphorylation sites that decrease 
and those that are CK2 substrates suggests divergent function of CX-4945 with respect to 
CK2-dependent processes.  
3.3 Discussion 
Protein kinase CK2 expression is de-regulated in different types of human cancers, as 
evidenced by a recent study of mRNA expression data in the Oncomine database (14). CK2 
is implicated in the regulation of different cellular pathways by virtue of the identification of 
protein substrates bearing the specificity determinants for phosphorylation (15). Given the 
signaling network that CK2 is involved in, it has emerged as a therapeutic target. CX-4945 is 
the first clinical-stage, orally-bioavailable small molecule ATP-competitive inhibitor of CK2 
(44). Therefore, we sought to use phosphoproteomics to profile CX-4945 treatment in HeLa 
cells to identify dynamic markers of CK2 activity and to monitor the effect of CK2 inhibition 
on signaling pathways, in addition to profiling potentially divergent (CK2 independent) 
functions of CX-4945 in cells.  
Initial profiling of CX-4945 in HeLa cells revealed a window of time of up to 240 
minutes where signaling events associated with apoptosis or DNA damage were not 
activated, suggesting CX-4945 dependent effects would be the primary stimulus for signaling 
events occurring. Utilizing a phospho-specific antibody for the bona fide CK2 substrate 
EIF2S2, confirmation of CK2 inhibition suggested that CX-4945 treatment antagonized CK2 
activity in HeLa cells. Subsequent analysis of quantified phosphorylation sites that changed 
in response to CX-4945 in HeLa revealed several sites that displayed dynamic levels of 
  
75 
reduced phosphorylation to a greater extent than that of EIF2S2 Ser2. Among theses sites 
that change dramatically, a well-characterized substrate of CK2 such as TOP2A Ser1377 
(135), decreased approximately 8 times more than DMSO vehicle treatment, suggesting that 
inhibition of CK2 was achieved. Utilizing KinomeXplorer and Phoxtrack, three 
phosphorylation sites matching the specificity determinants of CK2 were quantified from 
EIF2S2: Ser2, Ser67 and Thr111. Both Ser2 and Ser67 are annotated in the PhosphoSitePlus 
database as substrates of CK2 and both have been previously validated in experimental 
studies (134, 143). By comparison, although detected in previous studies, Thr111 as a 
substrate of CK2 has remained unexplored. Thr111 shows the largest change in response to 
CX-4945, and the rate of de-phosphorylation over the 240 minute treatment differs between 
Ser2 and Thr111 (Ser67 was not quantified in all time-points), suggesting differential activity 
towards these phosphorylation sites by protein phosphatases, given that CK2 has constitutive 
activity in cells (16). Ser2 and Ser67 have been identified as substrates of protein 
phosphatase-1 (144) while the phosphatase activity towards Thr111 remains to be 
determined. Ser2 has been characterized as a CK2β-dependent phosphorylation site and 
cannot be phosphorylated by the free catalytic subunit CK2α (11), which raises interesting 
questions regarding the de-phosphorylation of sites that are dependent on holo-enzyme 
activity versus catalytic subunits when cells are treated with an inhibitor of CK2. It should be 
noted that a few CK2 phosphorylation sites appear to increase in response to CX-4945 
treatment. This may be the result of a loss of phosphorylation on a multiply-phosphorylated 
peptide which increases the stoichiometry of a corresponding doubly or singly 
phosphorylated peptide at a different phospho-acceptor residue on the peptide. This trend has 
been previously identified with a different inhibitor of CK2, quinalizarin (127). Another 
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possibility might be the proximity of other phospho-acceptor residues serving as specificity 
determinants for hierarchical phosphorylation by CK2 (145), that when de-phosphorylated 
result in an apparent increase in phosphopeptide containing the CK2 phosphorylation site. 
More importantly, the phosphorylation sites that demonstrate the largest change in de-
phosphorylation not only serve as useful indicators of activity in cells but also provide further 
insight into the critical pathways that CK2 can regulate as these sites would be indicative of 
rapid turnover in regards to phosphatase activity. Previous investigations into large-scale 
phosphorylation stoichiometry in cells identified sites matching CK2 motifs possessing the 
highest phosphorylation stoichiometry in comparison to other kinases identified (146). The 
ability to quantify the proteome in parallel enabled the confident analysis of phosphorylation 
sites displaying dynamic regulation as it was determined that protein abundance during the 
length of CX-4945 treatment did not differ. 
Treatment with CX-4945 results in a dynamic phosphoproteome, creating changes in 
phosphorylation sites that can be attributed to kinases other than CK2. Interestingly, CK2 can 
regulate the activity of other kinases through phosphorylation of cdc37 Ser13, which in 
conjuction with Hsp90 can stabilize client kinases (136). Quantification of cdc37 Ser13 
phosphorylation did not change dramatically in response to CX-4945 treatment at 60 
minutes, suggesting that the dynamic regulation of phosphorylation sites attributed to other 
kinases is not necessarily through a CK2-dependent inhibition mechanism via the 
phosphorylation status of cdc37 Ser13. Analysis of the phosphoproteome using 
PHOXTRACK revealed that the activity of kinases such as mTOR and Akt are down-
regulated upon treatment with CX-4945. CK2 is known to phosphorylate Ser129 on Akt and 
this phosphorylation has been reported to contribute to Akt activity (147) which may provide 
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an explanation for the decreased phosphorylation of Akt substrates following CX-4945 
treatment. Previous reports utilizing CX-4945 demonstrated down-regulation of mTOR 
substrates in different cancer lines after a period of 240 minutes (44, 51), and are in 
agreement with the phosphoproteomic data presented here. Long term treatment of CX-4945 
can result in autophagy, as documented by Kim et al (148). Through phosphorylation of 
ULK1 Ser638, mTOR can repress autophagy activation (149), and given that ULK1 Ser638 
decreased in phosphorylation after 60 minutes of CX-4945 treatment, the possibility for a 
CK2-independent activation of autophagy exists with CX-4945 treatment. Another 
interesting phosphorylation site that may be attributable to mTOR activity is EIF5B Ser214, 
which showed drastic de-phosphorylation in response to CX-4945 but displays specificity 
determinants for CK2. A recent study investigating the phosphoproteome in cells treated with 
rapamycin for 2 hours found decreased phosphorylation of EIF5B Ser214, suggesting this 
site is a target of mTOR (150). This information raises speculation about the promiscuity of 
CX-4945 in cultured human cells, although IC50 values for kinases in the PI3K/Akt pathway 
and mTOR that were assayed in vitro were more than 500 times higher than for CK2 (44).  
Phosphorylation sites that showed an increase in response to CX-4945 treatment were 
attributed to CDK1 and CDK2 kinases. These results are interesting considering that CK2 is 
known to phosphorylate Cyclin H in the Cyclin-dependent kinase (CDK) Activating 
Complex (CAK) to regulate the activity of this complex (151), which is required for cell 
cycle progression through phosphorylation of CDK1 and CDK2 at Thr160/161 (reviewed in 
(152)). Inhibition of CK2 would suggest a decrease in CAK activity and therefore a decrease 
in CDK1 and CDK2 activity. One plausible consideration is the activity of phosphatase 
cdc25C, which can remove inhibitory phosphorylation at Thr14 and Tyr15 (reviewed in 
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(153)). Phosphorylation of cdc25C by CK2 at Thr236 results in delayed cytoplasmic-to-
nuclear transfer of cdc25C, and inhibition of CK2 in vivo results in enhanced nuclear 
localization (154), consistent with the suggestion that treatment with CX-4945 inhibits CK2 
phosphorylation of cdc25C, enabling increased activity towards the removal of inhibitor 
phosphorylation on CDK1 and CDK2. More recent experiments investigating cdc25C 
expression levels determined that long-term treatment with CK2 inhibitors actually decreases 
the levels of cdc25C and CDK1 (155). Given the short period of time in which HeLa cells are 
treated with CX-4945 in this phosphoproteomic investigation, and the utilization of an 
asynchronous population, subtle differences in cell cycle regulation may be more apparent in 
comparison to cells that have been treated for extended periods of time with inhibitor.   
A topological analysis of biological processes and pathways affected by CX-4945 
performed using gene enrichment analysis revealed widespread impact on the 
phosphoproteome. The enrichment of terms from biological processes derived from 
phosphorylation sites which increased were nuclear transport, RNA splicing, negative cell 
cycle regulation, apoptotic execution and microtubule regulation. Not surprisingly, CK2 is 
known to oppose apoptosis, given that it can translocate to the nucleus following DNA 
damage (37) and overexpression of CK2α can promote resistance to TRAIL-induced 
apoptosis (34, 156, 157). The large number of phosphorylation sites that increase on proteins 
enriched in these pathways can be interpreted as an extensive cellular response to CX-4945, 
attributable to the inhibition of not only CK2 but through the up-regulation and de-regulation 
of kinases in response to CX-4945. 
Phosphorylation sites that decreased were located on proteins involved in mRNA 
splicing, mTOR signaling, cytoskeletal organization, chromosome maintenance and nuclear 
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envelope formation. It is interesting to note that a recent report demonstrated that CX-4945 
regulated mRNA splicing independent of CK2 inhibition and that this could be attributed to 
the inhibition of Clk (Cdc2-like-kinase) kinases (158), although CK2 is known to 
phosphorylate and regulate the activity of RNA splicing activator RNPS1 (159) and has a 
large number of in vitro proteins that are involved in splicing (160). The enrichment of 
processes specific to proteins identified as CK2 substrates that decreased in response to CX-
4945 was divergent from the group of phosphorylation sites that decreased overall, with 
enrichment in DNA repair and translation processes. CK2 constitutively phosphorylates 
several proteins involved in DNA repair, such as XRCC1 (161), XRCC4 (39), and MDC1 
(29), which generates binding sites for FHA (Fork-head associated) domains to recruit other 
factors to sites of DNA repair. These data collectively suggest that inhibition of CK2 with 
CX-4945 in HeLa cells primarily results in drastic de-phopshorylation of proteins involved in 
DNA repair and translation, with secondary effects that are putatively CK2-independent with 
respect to processes involved with mRNA splicing and mTOR signaling for that matter.  
The investigation of CX-4945 using phosphoproteomics in HeLa cells has revealed a 
substantial impact of this CK2 inhibitor in the regulation of phosphorylation of protein 
involved in broad range of biological processes. Utilizing bioinformatics tools, the 
identification of dynamic markers of CK2 activity was achieved; noting that many of these 
phosphorylation sites exhibited de-phosphorylation of a greater magnitude than previously 
standardized substrates. A number of interesting responses in the phosphoproteome were 
elicited, with many of these changes in phosphorylation sites attributed to other kinases, 
suggesting a divergence of specificity for CX-4945 in HeLa cells. Taken together these 
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findings demonstrate the utility of phosphoproteomics to characterize the effects of a small-
molecule ATP-competitive inhibitor. 
3.4 Experimental Methods 
3.4.1 Cell Culture, Lysis & Western Blotting for Preliminary 24 Hour CX-4945 
Treatment 
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100 
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945 (MedKoo Biosciences) 
from at various intervals from 1 to 24 hours. Media was vacuum-aspirated and cells were 
washed with ice cold PBS, followed by lysis on ice [1% octyl-β-D-glucopyranoside (Sigma-
Aldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane) (Bioshop) pH 8.5, 6 M urea 
(Sigma-Aldrich), 25 mM β-glycerophosphate (Bioshop), 1 µM okadaic acid (Bioshop), 50 
mM sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR (Cayman Chemical), 10 mM 
sodium orthovanadate (Sigma-Aldrich), 5 mM sodium pyrophosphate (Sigma-Aldrich), 
pepstatin (10 µg/mL) (Sigma-Aldrich)]. Samples were sonicated 2 x 15 seconds on ice then 
spun for 10 minutes at 16,000 x g at 4 °C. The supernatant was retained and protein 
concentration was determined using a Bradford assay (Bio-Rad). An equal amount of each 
sample (20 µg) was loaded per lane and separated by SDS-PAGE. Proteins were transferred 
to PVDF membrane (Millipore) using a wet-transfer apparatus (Bio-Rad) at 400 mA for 60 
minutes at 4 °C followed by incubation in blocking buffer (LI-COR Biosciences) for 60 
minutes. Primary antibodies were incubated overnight at 4 °C in 3% BSA-TBST or 3% BSA-
PBST. Antibodies against PARP (9542, Cell Signaling Technologies), γH2AX S139 
(ab26350, Abcam), GAPDH (MAB374, Millipore) and pEIF2S2 S2 (YenZym Laboratories, 
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raised against ac-pS-GDEMIFDPTMSKC-amide) were used. Secondary antibodies used 
were GAR-800 (926-32211), GAM-800 (926-32210), and GAM-680 (926-32220) (LI-COR 
Biosciences) in 3% BSA-TBST or 3% BSA-PBST, with incubation for 45 minutes.  
Following 3 x 5 minute washes with TBST or PBST, membranes were scanned using an 
Odyssey scanner (LI-COR Biosciences) at 700 nm and 800 nm wavelengths. Raw data scans 
were loaded into ImageStudioLite v5.2.5 (LI-COR Biosciences) and exported as .TIFF image 
files.  
3.4.2 SILAC Medium Formulation 
SILAC-dropout DMEM (Life Technologies) lacking L-arginine, L-lysine and L-
glutamine was supplemented with isotope-encoded L-arginine (13C6) and L-lysine (4,4,5,5-
D4) (Cambridge Isotope Laboratories Inc.) at respective concentrations of 86.2 mg/L (0.398 
mM) and 61.16 mg/L (0.274 mM) to create a “heavy” medium. “Light” medium was created 
using the SILAC-dropout DMEM by supplementing with equivalent molar amounts of 
unlabeled L-arginine (83.9 mg/L) and L-lysine (60.04 mg/L). All media used for SILAC 
studies were supplemented with 10% 10 kDa-dialyzed FBS (Corning), penicillin (100 
U/mL), streptomycin (100 mg/mL), L-glutamine (2 mM) (Life Technologies), and L-proline 
(400 mg/L) (Cambridge Isotope Laboratories Inc.) in order to prevent arginine to proline 
conversion (131, 162). Media was filter-sterilized prior to use for cell culture.  
3.4.3 SILAC Incorporation of HeLa Tet-Off Cells 
HeLa Tet-Off cells were adapted over a period of 7 days with 3 sub-passages after being 
switched to SILAC medium. An aliquot of protein lysate from heavy labeled cells was 
precipitated using 6 sample volumes of 10% TCA in acetone (v/v) and digested on-pellet 
(refer to Chapter 2.4.7 for digestion procedure). Trypsin-Lys-C (Promega) at 200:1 (w/w) 
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was used for the first 4 hour digestion step and Trypsin at 100:1 (Pierce) was used for the 
overnight incubation step. Digested peptides were desalted using a C18 StageTip (Empore) 
(163). LC-MS/MS parameters for data acquisition followed those presented in Chapter 
2.4.10, with data acquisition performed on an Orbitrap Elite mass spectrometer. Raw spectra 
were analyzed using MaxQuant v1.5.3.8 (70, 71, 164) and searched against the Swissprot-
Uniprot sequence database (homo sapiens taxon, accessed on December 26, 2015). Samples 
were searched using a Multiplicity set to 2, with “heavy” labels selected as Arg6 and Lys4. 
Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the 
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7, 
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease 
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The 
number of variable modifications per peptide was 5, with methionine oxidation (+15.9949), 
protein N-terminus acetylation (+42.0105), asparagine and glutamine deamidation (+0.9840 
Da) selected. Cysteine carbamidomethylation (+ 57.0215) was set as a fixed modification. 
Re-Quantify option was turned on. The minimum score for modified peptides was set to 40, 
and the decoy-database setting was “Revert.” Output data from MaxQuant was then loaded 
into Perseus version 1.5.2.6 (121). The “evidence.txt” file was used to extract information 
about peptides that were quantified in MS1 and identified in MS2, from which reverse hits 
and contaminants were removed. The heavy and light intensity values from MS1 quantitation 
were used to calculate H/L ratios. Two formulae were applied to calculate the incorporation 
for each peptide: H/L ratios larger than 1 were calculated with (100 – (1/ratio)*100), and 
ratios less than 1 were calculated with (ratio * 100). The median of all incorporation values 
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for each individual SILAC pair was calculated and represents the incorporation efficiency for 
the labeled amino acids. 
3.4.4 CX-4945 Treatment and Lysis of SILAC HeLa Tet-Off Cells 
HeLa Tet-Off cells were cultured in heavy or light-labeled SILAC medium. Cells 
were maintained in 15 cm cell culture plates until reaching approximately 80% confluence. 
Heavy labeled cells were treated with 20 µM CX-4945 (MedKoo Biosciences) for 60, 135, 
180 and 240 minutes, with light labeled cells treated with DMSO vehicle. Three 15 cm plates 
(representing three independent biological replicates) were harvested for each labeled 
population for each time-point. Following treatment, media was vacuum-aspirated and cells 
were washed with ice cold PBS, followed by lysis on ice in 750 µL of lysis buffer [1% octyl-
β-D-glucopyranoside (Sigma-Aldrich), 50 mM Tris (tris(hydroxymethyl)aminomethane) 
(Bioshop) pH 8.5, 6 M urea (Sigma-Aldrich), 25 mM β-glycerophosphate (Bioshop), 1 µM 
okadaic acid (Bioshop), 50 mM sodium fluoride (Sigma-Aldrich), 1 µM microcystin-LR 
(Cayman Chemical), 10 mM sodium orthovanadate (Aldrich), 5 mM sodium pyrophosphate 
(Sigma-Aldrich), pepstatin (10 µg/mL) (Sigma-Aldrich)]. Samples were sonicated for 2 x 15 
seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C.  The supernatant was retained 
and protein concentration was determined using a Bradford assay (Bio-Rad). Samples were 
frozen at – 80 °C until processing. 
3.4.5 Western Blotting of CX-4945 Treated Samples for Phosphoproteomics 
An equal amount of each sample (20 µg) was loaded per lane and separated by SDS-PAGE. 
Proteins were transferred to PVDF membrane (Millipore) using a wet-transfer apparatus 
(Bio-Rad) at 400 mA for 60 minutes at 4 °C followed by block in blocking buffer (LI-COR 
Biosciences) for 60 minutes. Primary antibodies were incubated overnight 4 °C in 3% BSA-
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TBST or 3% BSA-PBST. Antibodies against PARP (9542, Cell Signaling Technologies), 
γH2AX S139 (ab26350, Abcam), GAPDH (MAB374, Millipore), pATM S1981 (ab81292, 
Abcam), hVIN1 (V9131, Sigma) and pEIF2S2 S2 (YenZym Laboratories, raised against ac-
pS-GDEMIFDPTMSKC-amide) were used. Secondary antibodies used were GAR-800 (926-
32211), GAM-800 (926-32210), and GAM-680 (926-32220) (LI-COR Biosciences) in 3% 
BSA-TBST or 3% BSA-PBST, with incubation for 45 minutes. Data was acquired as 
previously outlined in Chapter 3.4.1. Lysates derived from unlabeled HeLa Tet-Off cells 
treated with staurosporine (2 µM) (LC Laboratories), 20 ng/mL neocarzinostatin (Sigma), or 
DMSO (Fisher) for 3 hours were used as controls.  
3.4.6 Sample Digestion and Phosphopeptide Enrichment 
Prior to sample processing, 2 mg of protein lysate derived from light labeled cells 
(DMSO treated) and 2 mg of protein lysate derived from heavy labeled cells (CX-4945 
treated) from each respective biological replicate was mixed, resulting in 12 samples. 
Samples were then processed using protein precipitation, and digested following the methods 
outlined in Chapter 2.4.7 with some alterations. Trypsin-Lys-C (Promega) at 200:1 (w/w) 
was used for the first 4 hour digestion step and Trypsin at 100:1 (Pierce) was used for the 
overnight incubation step. Phosphopeptides were enriched following the methods outlined in 
Chapter 2.4.8.  
3.4.7 LC-MS/MS Data Acquisition 
Samples were analyzed using an Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer 
using the acquisition parameters and settings previously described in Chapter 2.4.10. Three 
biological replicates per time-point were analyzed in technical duplicate, generating a total of 
96 raw mass spectra files. Raw mass spectra files were analyzed in MaxQuant version 1.5.3.8 
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(70, 71, 164) and searched against the Swissprot-Uniprot sequence database (homo sapiens 
taxon, accessed on December 26, 2015). Samples were searched using a Multiplicity set to 2, 
with “heavy” labels selected as Arg6 and Lys4. Mass tolerances were set to 4.5 ppm for the 
parent ion mass (MS) and 0.5 Da for the fragment ion mass (MS/MS). The minimum number 
of amino acids in a peptide was set to 7, with a peptide spectrum match (PSM) and protein 
match set to 1% FDR and protease selectivity for trypsin/P. A maximum number of 3 missed 
cleavages was selected. The option for second peptide search was selected, as was the use of 
“Match Between Runs” for respective pairs of samples between biological replicates, using 
the default matching parameters. Raw mass spectra files were defined as separate groups 
using the experimental setup option. Cysteine carbamidomethylation (+ 57.0215 Da) was set 
as a fixed modification. For phosphopeptide samples, the number of variable modifications 
per peptide was 6, with methionine oxidation (+15.9949 Da), protein N-terminus acetylation 
(+42.0105 Da), asparagine and glutamine deamidation (+0.9840 Da) and serine, threonine, 
and tyrosine phosphorylation (+79.9663) selected. For proteome samples the maximum 
number of variable modifications was set to 5, and phosphorylation as a variable 
modification was excluded from these samples. The minimum score for modified peptides 
was set to 40, and the decoy-database setting was “Revert.” For quantification of protein 
groups, unmodified peptides and those with carbamidomethylation, methionine oxidation, 
protein N-terminus acetylation or asparagine and glutamine deamidation were included. 
Peptides for which the corresponding heavy or light modified peptide were not quantified 
were excluded from the protein groups quantitation. Output data from MaxQuant was then 
loaded into Perseus version 1.5.2.6 (121). For the analysis of proteome data, the 
“proteinGroups.txt” file was first processed to remove entries marked as reverse decoy 
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database hits, contaminants, and protein identifications that were only matched to modified 
peptides. MaxQuant-generated normalized ratios were utilized, and the log base 2 of the 
normalized ratios was calculated for each protein. Proteins were considered identified in each 
biological replicate if identified in at least one of two technical replicates. For the analysis of 
the phosphoproteome data, the “Phospho (STY)Sites.txt” file was first processed to remove 
entries marked as reverse decoy database hit and contaminants, and filtered to only contain 
phosphorylation sites with localization probability greater than 0.75. Phosphorylation sites 
were expanded in Perseus to obtain information from instances of quantified sites being 
derived from singly, doubly and triply-phosphorylated peptides. Rows where no 
quantification was present were removed, and phosphorylation sites were considered 
quantified in each biological replicate if they were identified in at least one of two technical 
replicates. 
3.4.8 Data Analysis 
A one-sample Student’s t-test with multiple hypothesis correction using Benjamini Hochberg 
FDR = 0.05 was used to identify statistically significant phosphorylation sites that responded 
to CX-4945 treatment for each respective time-point dataset. A list of all phosphosites 
identified with putative upstream kinases was generated using KinomeXplorer (77) following 
criteria outlined in Schoof et al. (165) for kinase prediction and filtering, excluding 
prediction scores for a phosphorylation site that was less than 1 and predicting only one 
kinase per site. Phosphoproteomic and proteomic data were visualized using the ggplot2 
package within the R framework (v3.2.3). PHOXTRACK (128) was used to identify kinase-
substrate relationships that are indicative of up or down-regulation of kinases. The 
PhosphositePlus database (138, 166) was queried with uploaded mean log2 ratios of 
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phosphorylation sites from each time-point dataset. An unweighted Kolmogorov-Smirnov 
running sum statistic was calculated for the query list of phosphorylated sites with the 
number of permutations set to 10,000 and the minimum number of phosphosites per kinase 
set to 3 with, retaining kinase hits which were < 0.25 FDR and the respective information of 
the phosphorylation mark with the upstream kinase. To perform gene enrichment analysis, 
statistically significant phosphorylation sites across all time-points were grouped together 
into three groups: sites which increased greater than log2 ratio 1, sites which decreased 
greater than log2 ratio -1, and sites that decreased greater than log2 -1 and were identified as 
CK2 phosphorylation sites. Gene identifiers from these phosphorylation sites were queried 
with g:Profiler (129), using the following parameters: the minimum and maximum size of 
functional category was 5 and 500 respectively, no electronically inferred GO annotations, 
only significant hits displayed, hierarchical filtering enabled, minimum size of gene list and 
functional category overlap was 2, significance threshold was set to Benjamini Hochberg and 
GO biological process, KEGG pathways and Reactome pathways were queried. The output 
was saved in generic enrichment map format and loaded into Cytoscape v3.3.0 (167). 
Enriched biological processes and pathways were visualized using the EnrichmentMap 
v2.1.0 plugin (142), building the network with minimum similarity score of 0.5 and 
maximum q-value (FDR adjusted P value) of 0.005 The AutoAnnotate v1.1.0 plugin (168) 
was used to generate word-clouds depicting over-represented terms in the biological 
processes and pathways that were clustered together in order to summarize terms for each 
cluster.  
3.5 Supplemental Figures  
 
  
88 
 
Supplemental Figure 3.1 Frequency Distribution of SILAC Arginine and Lysine 
Incorporated Peptides. 
HeLa cells were adapted in SILAC medium over 7 days with 3 sub-passages. An aliquot of 
heavy labeled cells was processed as described in 3.4.3. Distribution is representative of all 
arginine and lysine peptides that were quantified. Red vertical line indicates 95% 
incorporation. Median incorporation was calculated as 96.47 %.  
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Supplemental Figure 3.2 Preliminary Time-Course Treatment of HeLa Cells with 20 
µM CX-4945. 
HeLa cells were treated for intervals up to 24 hours with CX-4945 followed by lysis. Lysates 
were separated by SDS-PAGE, transferred and western blotted using antibodies against 
PARP, GAPDH, γH2AX and phospho-EIF2S2. Refer to 3.4.1 for methods. 
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Supplemental Figure 3.3 Biological Replicate 1 of SILAC Labeled Cells Treated with 
CX-4945 and Analyzed by LC-MS/MS. 
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were 
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or 
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods. 
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Supplemental Figure 3.4 Biological Replicate 2 of SILAC Labeled Cells Treated with 
CX-4945 and Analyzed by LC-MS/MS. 
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were 
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or 
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods. 
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Supplemental Figure 3.5 Biological Replicate 3 of SILAC Labeled Cells Treated with 
CX-4945 and Analyzed by LC-MS/MS. 
Heavy labeled HeLa cells were treated with 20 µM CX-4945 and light labeled cells were 
treated with DMSO for indicated times. HeLa cells treated with staurosporine (STS) or 
neocarzinostatin (NCS) served as positive controls. Refer to 3.4.5 for methods. 
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Supplemental Figure 3.6 Frequency Distribution of Phosphorylation Site Mean Log2 
Ratio In HeLa Cells Treated with CX-4945 for 60 Minutes. 
The mean log2 ratio of three biological replicates for each site identified and quantified is 
represented in this frequency distribution of all quantified sites from HeLa cells treated with 
20 µM CX-4945 for 60 minutes. Numbers correspond to sites down or up-regulated in Figure 
3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites. 
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Supplemental Figure 3.7 Frequency Distributino of Phosphorylation Site Mean Log2 
Ratio In HeLa Cells Treated with CX-4945 for 135 Minutes. 
The mean log2 ratio of three biological replicates for each site identified and quantified is 
represented in this frequency distribution of all quantified sites from HeLa cells treated with 
20 µM CX-4945 for 135 minutes. Numbers correspond to sites down or up-regulated in 
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites. 
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Supplemental Figure 3.8 Frequency Distribution of Phosphorylation Site Mean Log2 
Ratio In HeLa Cells Treated with CX-4945 for 180 Minutes. 
The mean log2 ratio of three biological replicates for each site identified and quantified is 
represented in this frequency distribution of all quantified sites from HeLa cells treated with 
20 µM CX-4945 for 180 minutes. Numbers correspond to sites down or up-regulated in 
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites. 
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Supplemental Figure 3.9 Frequency Distribution of Phosphorylation Site Mean Log2 
Ratio in HeLa Cells Treated with CX-4945 for 240 Minutes. 
The mean log2 ratio of three biological replicates for each site identified and quantified is 
represented in this frequency distribution of all quantified sites from HeLa cells treated with 
20 µM CX-4945 for 240 minutes. Numbers correspond to sites down or up-regulated in 
Figure 3.2 C. Coloured arrows correspond to increasing, decreasing or decreasing CK2 sites. 
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Supplemental Figure 3.10 Frequency Distribution of Protein Mean Log2 Ratio in HeLa 
Cells Treated with CX-4945 for 60 Minutes. 
The mean log2 ratio of three biological replicates for each protein identified and quantified is 
represented in this frequency distribution of all quantified proteins from HeLa cells treated 
with 20 µM CX-4945 for 60 minutes. 
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Supplemental Figure 3.11 Frequency Distribution of Protein Mean Log2 Ratio in HeLa 
Cells Treated with CX-4945 for 135 Minutes. 
The mean log2 ratio of three biological replicates for each protein identified and quantified is 
represented in this frequency distribution of all quantified proteins from HeLa cells treated 
with 20 µM CX-4945 for 135 minutes. 
  
  
99 
 
Supplemental Figure 3.12 Frequency Distribution of Protein Mean Log2 Ratio in HeLa 
Cells Treated with CX-4945 for 180 Minutes. 
The mean log2 ratio of three biological replicates for each protein identified and quantified is 
represented in this frequency distribution of all quantified proteins from HeLa cells treated 
with 20 µM CX-4945 for 180 minutes. 
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Supplemental Figure 3.13 Frequency Distribution of Protein Mean Log2 Ratio in HeLa 
Cells Treated with CX-4945 for 240 Minutes. 
The mean log2 ratio of three biological replicates for each protein identified and quantified is 
represented in this frequency distribution of all quantified proteins from HeLa cells treated 
with 20 µM CX-4945 for 240 minutes. 
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Supplemental Figure 3.14 Companion Figure for Figure 3.16 
Biological process terms are shown for each node in the network. 
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Supplemental Figure 3.15 Companion Figure for Figure 3.17 
Biological process terms are shown for each node in the network. 
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4 Chapter 4 – Functional Characterization of the Kinome in Response to CX-4945 
Treatment 
4.1 Introduction 
Protein kinases play a critical role in the regulation of cellular processes through the 
phosphorylation of proteins. Historically, strategies have focused on the modulation of 
individual phosphorylation sites by individual kinases in distinct cellular contexts. The 
emergence of high-throughput phosphoproteomic analyses using mass spectrometry has 
enabled the quantitative profiling of the phosphorylation status of thousands of modified sites 
in the proteome, and can deliver insights into signaling mechanisms at play in the regulation 
of a protein’s function at a network level (56). In such approaches the regulation of kinases 
has been studied through the interpretation of the modulation of phosphorylation sites in 
distinct cellular contexts or using kinase inhibitors (72, 73). Furthermore, recent 
developments in chemical proteomics and mass spectrometry have enabled the enrichment 
for kinases to enable profiling of kinase expression and activity at the level of the kinome.  
One of the strategies for kinome profiling exploits multiplexed inhibitor beads (MIBs) (82, 
83). Multiplexed inhibitor beads consist of sepharose beads conjugated with ATP-
competitive inhibitors that have a broad range of specificity, which enables the capture of a 
large number of protein kinases. When coupled with LC-MS/MS, MIBs enable the 
quantitative profiling of kinase activity within a cellular context. MIBs can also be applied to 
evaluate kinome responses in cells treated with kinase inhibitors and for the systematic 
profiling of kinase inhibitor specificity (169).  
In an effort to relate responses to CX-4945 that were identified using phosphoproteomics in 
the previous chapter, MIB profiling was undertaken to study the effect of CX-4945 at the 
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kinome level. Two complementary sample preparation approaches were utilized in order to 
profile the kinome of HeLa cells that were treated with CX-4945 for 240 minutes. Utilizing 
MIBs enables the quantitative comparison of the amount of kinase bound to the inhibitor 
resin, enabling identification of kinases that are up-regulated or down-regulated in response 
to inhibitor treatment. Given the enrichment of kinases in comparison to the general 
proteome, MIB profiling also enables the identification of phosphorylated kinases, lending 
more insight into kinase activity, particularly for the many kinases that are regulated by 
phosphorylation (170). Our studies have also incorporated utilization of another CK2 
inhibitor “Inhibitor VIII,” which was designed using virtual screening and structure-based-
guided methods (87). Inhibitor VIII was exploited for discrimination between CK2-
dependent or CK2-independent effects of CX-4945 within the CX-4945 dependent 
phosphoproteome that was characterized in Chapter 3. 
4.2 Results 
4.2.1 Multiplexed Inhibitor Bead Profiling Reveals Kinome Perturbation in Response 
to CX-4945 
In an effort to complement previous phosphoproteomic analysis of CX-4945 in HeLa cells, 
multiplexed inhibitor bead (MIB) profiling was performed utilizing two different inhibitor-
based MIB resins that have been previously described (171, 172). This workflow consisted of 
treating SILAC labeled HeLa cells for 240 minutes with either CX-4945 or DMSO. Three 
biological replicates consisting of heavy-labeled cells (CX-4945 treated) and light-labeled 
cells (DMSO treated) were profiled using the six-inhibitor mix and the four-inhibitor mix, 
resulting in two datasets. A separate experiment consisting of one biological replicate with 
heavy-labeled cells (DMSO treated) and light-labeled cells (CX-4945 treated) was profiled 
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using the four-inhibitor mix (Figure 4.1). MIB profiling enables the capture of active kinases 
to the inhibitor resin, allowing quantitative comparison by LC-MS/MS of labeled peptides 
derived from the captured kinases within a given biological context (84). Utilizing these two 
different inhibitor resins, profiling of SILAC labeled HeLa cells revealed regulation of kinase 
activity in response to CX-4945 treatment, quantifying between 148-217 kinases in separate 
analyses (Figure 4.2) in addition to 30-77 phosphorylation sites that were identified on 
kinases. The identification of several kinases related to the PI3K/Akt/mTOR pathways that 
decreased in activity in response to CX-4945 supported the data previously presented in 
chapter 3 which quantified a decrease in phosphorylation on substrates of these kinases 
(Figure 4.3, Figure 4.5, Figure 4.7). Kinases such as AKT1 (Akt1), SGK1 (Sgk1), and 
RPS6KB1 (p70S6K) decreased approximately 25% (log2 value of -0.4) in response to CX-
4945, suggesting that inhibition of mTOR occurred with CX-4945 treatment (173-175). 
Pyruvate kinase (PKM), which regulates glycolysis and can be controlled by mTOR activity 
(176), decreased approximately 3x (log2 value of -1.5).  Interestingly, the decrease in CK2 
activity (CSNK2A1) was approximately 25%, suggesting that MIB profiling was able to 
detect inhibition of CK2 in cells treated with CX-4945. Quantification of CK2 activity was 
only detected in samples processed using the six-inhibitor mix. Samples profiled using the 
four-inhibitor mix revealed other targets that could be regulated by mTOR, with a decrease in 
Akt2 activity of approximately 30%, and an increase in Ulk1 activity of approximately 100% 
(Figure 4.7). The change in activity of kinases regulated by mTOR further supports the 
notion that CX-4945 treatment results in down-regulation of mTOR.  
The capture of kinases using MIBs enabled the identification and quantification of 
phosphorylation sites located on kinases that was not previously documented using the 
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phosphoproteomics workflow presented in chapter 3, owing largely in part to constraints in 
detecting lower-abundance proteins in data-dependent acquisition of a complex lysate 
mixture (170). Treatment with CX-4945 resulted in the increase of phosphorylation on 
several kinases that are a part of the mitogen activated protein kinase (MAPK) pathway 
(Figure 4.4). Thr185/Tyr187 of MAPK1 (ERK2) and Thr202/Tyr204 of MAPK3 (ERK1) 
increased in phosphorylation more than 2x, with a downstream target of ERK, RPS6KA1 
Ser380 increasing almost 4x in phosphorylation, suggesting activation of the MAPK pathway 
after treatment with CX-4945. The increase in MAPK1 phosphorylation sites was 
documented using the four-inhibitor MIB beads as well (Figure 4.6). In addition to the 
quantification of phosphorylation sites on kinases from MAPK pathway, the quantitation at 
the protein level for interleukin-1 receptor-associated kinase (IRAK1) demonstrated a large 
increase that was detected using both MIB mixes (Figure 4.3, Figure 4.5). The activity of 
IRAK1 has been demonstrated to be required for the phosphorylation of ERK1/2 in the 
context of interleukin-mediated signaling (177). Lysates used for proteomic profiling were 
analyzed using western blotting, probing against different constituents of the MAPK pathway 
using phospho-specific antibodies (Figure 4.9). These results corroborate the quantification 
of the phosphorylation sites from kinases captured by the MIBs.  
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Figure 4.1 Workflow Overview for Multiplexed Inhibitor Bead Profiling 
SILAC-adapted HeLa cells were treated with CX-4945 or DMSO for 240 minutes followed 
by lysis. Samples were combined 1:1 based on protein amount and processed using MIBs 
that contained either a 6-Inhibitor or 4-Inhibitor mix. Peptides derived from captured kinases 
were acquired by LC-MS/MS and raw mass spectra were quantified using MaxQuant 
v1.5.3.8.  
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Figure 4.2 Summary of Kinases Identified and Quantified by MIB Profiling 
Quantitative information from samples processed using the 6-Inhibitor mix was filtered on 
the basis of identification and quantification in two out of three biological replicates. For 
samples processed using the 4-Inhibitor mix, two out of three biological replicates were 
considered separately from the sample in which the light label was treated with CX-4945 and 
the heavy label was treated with DMSO. Phosphorylation sites were considered only if 
localization exceeded a probability of 0.75. 
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Figure 4.3 Quantification of Kinases Using 6-Inhibitor MIBs 
The mean log2 (CX-4945/DMSO) ratio is presented from 2 out of 3 biological replicates. 
Bars denote standard variation where quantitative information was obtained from 3 
biological replicates. Labeled kinases increased > log2 + 0.5 or decreased > log2 - 0.4.  
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Figure 4.4 Quantification of Kinase Phosphorylation Sites Using 6-Inhibitor MIBs 
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the 
database searching in MaxQuant but excluded in the quantification of protein groups. 
Phosphorylation sites that exceeded localization probability of 0.75 are presented. Blank 
squares denote values for phosphorylation sites where quantitation was not present in a 
biological replicate.  
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Figure 4.5 Quantification of Kinases Using 4-Inhibitor MIBs 
The mean log2 (CX-4945/DMSO) ratio is presented from 2 out of 3 biological replicates. 
Bars denote standard variation where quantitative information was obtained from 3 
biological replicates. Labeled kinases increased > log2 + 0.5 or decreased > log2 - 0.4.  
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Figure 4.6 Quantification of Kinase Phosphorylation Sites Using 4-Inhibitor MIBs 
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the 
database searching in MaxQuant but excluded in the quantification of protein groups. 
Phosphorylation sites that exceeded localization probability of 0.75 are presented. Blank 
squares denote values for phosphorylation sites where quantitation was not present in a 
biological replicate.  
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Figure 4.7 Quantification of Kinases Using 4-Inhibitor MIBs in Label Swap 
The mean log2 (CX-4945/DMSO) ratio is presented from the label swap, where light HeLa 
cells were treated with CX-4945. Labeled kinases increased > log2 + 0.5 or decreased > log2 
- 0.4.  
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Figure 4.8 Quantification of Kinase Phosphorylation Sites Using 4-Inhibitor MIBs in 
Label Swap 
Phosphorylation of Ser, Thr, and Tyr residues as a variable modification was included in the 
database searching in MaxQuant but excluded in the quantification of protein groups. 
Phosphorylation sites that exceeded localization probability of 0.75 are presented.  
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Interestingly, the increase of Tyr15 phosphorylation on CDK1 was detected in response to 
CX-4945 from singly phosphorylated peptides that were identified and quantified when 
profiling lysates using the six-inhibitor mix  (Figure 4.4). The Tyr15 phosphorylation site 
was quantified as decreasing in phosphorylation from doubly phosphorylated peptides which 
also contain phosphorylation at Thr14. Due to isoform similarity between the CDK-family 
kinases, the phosphopeptides which have the localized phosphorylation site match multiple 
CDK kinases. Using the four-inhibitor mix, the quantification of Tyr15 from multiply 
phosphorylated peptides decreased (Figure 4.6, Figure 4.8)..The quantitation of Tyr15 from 
singly phosphorylated peptides was only observed in samples profiled by the four-inhibitor 
mix when light-labeled cells were treated with CX-4945 in a label swap experiment. In this 
instance only a small increase in phosphorylation was observed in comparison to 
quantification obtained when samples were profiled using the six-inhibitor MIBs (Figure 4.6, 
Figure 4.8). Given the relative quantitation between singly and doubly phosphorylated 
peptides containing phosphorylated Tyr15, and the increase in the singly phosphorylated 
form of the Tyr15 site and decrease in the doubly phosphorylated form, this suggests an 
overall increase at this phosphorylation site on CDK. The phosphorylation of Tyr15 is 
inhibitory to the activity of CDK kinase (178) and can impede the progression from G2 to M 
phases of the cell cycle, suggesting that CX-4945 down-regulates the CDK1 activity after 
240 minutes of treatment.  
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Figure 4.9 MIBs Profiling Reveals Activation of the ERK MAPK Pathway in Response 
to CX-4945 
Western blot of samples utilized for MIB profiling. 10 µg of lysate was separated by SDS-
PAGE, transferred to PVDF membrane and probed against antibodies listed to the right of 
each panel. R1, R2, R3 and swap denote the four biological replicates that were processed. 
Heavy-labeled SILAC HeLa cells from replicates R1-R3 were treated with 20 µM CX-4945 
with light-labeled cells being treated with DMSO. In the label swap, treatment and control 
samples were switched.  
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4.2.2 CX-4945 and Inhibitor VIII Activate MAPK Pathway 
To test whether the activation of the MAPK pathway by CX-4945 was independent of 
CK2 inhibition, an unrelated small molecule inhibitor of CK2, “Inhibitor VIII” (87) was 
utilized in subsequent assays in parallel with CX-4945 treatment. Given that SILAC media 
requires growth conditions using FBS that is dialyzed against a 10 kDa membrane in order to 
prevent small unlabeled peptides or amino acids from interfering with the adaptation of 
heavy labeled amino acids, and that the presence of FBS in cell culture media can induce 
phosphorylation of constituents of the MAPK pathway, assays were performed with or 
without an overnight serum starve prior to inhibitor treatment. Treatment with 20 µM CX-
4945 or 15 µM Inhibitor VIII resulted in increased phosphorylation of ERK1/2, which was 
observed in tandem with decreased phosphorylation of EIF2S2 Ser2 (Figure 4.10). Following 
this observation, samples from this treatment were run against samples from HeLa cells 
treated with neocarzinostatin, staurosporine, MG-132 or torin to investigate whether this 
increase in phosphorylation was p38 MAPK-dependent, which can become activated in 
cellular stress contexts (179, 180) (Figure 4.11), and can be regulated by IRAK1 activity 
(177). Interestingly, unlike the treatment with neocarzinostatin or staurosporine, inhibition of 
CK2 utilizing CX-4945 or Inhibitor VIII for 240 minutes did not induce p38 MAPK 
phosphorylation on Thr180/Tyr182 suggesting a p38 MAPK-independent activation of 
ERK1/2. Phosphopeptides from p38 MAPK were detected using MIBs, although only the 
singly phosphorylated form with localized site Tyr182 which did not change (Figure 4.4, 
Figure 4.8). A differential decrease in phospho-4E-BP1 was also noted between CX-4945 
and Inhibitor VIII treated cells.  
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Figure 4.10 Activation of the ERK MAPK Pathway in Response to CX-4945 is 
Independent of Media Supplementation 
Parental HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. 
Cells were then treated with CX-4945 or Inhibitor VIII for 240 minutes. In parallel, HeLa 
cells were treated with 1 µM of proteasomal inhibitor MG-132 for 19 hours. All treatments 
were performed by delivering drugs that were diluted in cell culture media without FBS 
supplementation. Samples presented in this panel were collected in MIBs lysis buffer. 
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Figure 4.11 CX-4945 Activation of the ERK1/2 MAPK Pathway is Independent of p38 
MAPK 
Parental HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. 
Lysates from HeLa cells previously analyzed by western blotting in Figure 4.10 were re-
analyzed by western blotting in comparison to extracts derived from HeLa cells treated with 
staurosporine (STS), neocarzinostatin (NCS) or Torin1 at indicated concentrations for 4 
hours. All treatments were performed by delivering drugs that were diluted in cell culture 
media without FBS supplementation. Samples presented in this panel were collected in MIBs 
lysis buffer. 
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4.2.3 CX-4945 and Inhibitor VIII Display Differential Inhibition of Phospho-4E-BP1  
Having observed a decrease in phospho-4E-BP1 (Figure 4.11) and being unable to 
confidently identify changes in LC3-II (a marker of autophagy induction, which can be 
regulated through mTOR activity towards Ulk1 (181)), HeLa cells that were previously 
grown in the presence of FBS were treated with for 240 minutes with CX-4945, Inhibitor 
VIII and torin1, followed by sample collection using a lysis buffer containing different 
detergents. Lysates were probed with antibodies for components of the PI3K/Akt/mTOR 
signaling pathways (Figure 4.12). This experiment confirmed that treating HeLa cells with 
CX-4945 led to a decrease of phospho-4E-BP1 signal to a different extent than that seen with 
Inhibitor VIII despite both inhibitors decreasing the level of phospho-EIF2S2 to a similar 
extent. Torin1 and staurosporine abolished the presence of LC3-I (higher migrating band) 
and CX-4945 decreased this to a similar extent in comparison to Inhibitor VIII and DMSO 
control.  Despite poor resolution of the band by SDS-PAGE because of its high molecular 
weight, a decrease in phosphorylation of mTOR at Ser2448 is more noticeable in response to 
CX-4945 as compared to Inhibitor VIII treatment.  
4.2.4 CX-4945 Induces Rapid Activation of MAPK Pathway and Down-regulation of 
PI3K/Akt/mTOR Pathways  
Since previous investigation of CX-4945 treated HeLa cells covered time-points that spanned 
between 60 and 240 minutes, assays were performed within a window of time which 
preceded 60 minutes in order to explore whether CX-4945 effects would be evident. Indeed, 
the activation of the MAPK pathway was rapid, occurring within a span of 15 minutes as 
evidenced by increases in phosphorylation of ERK1/2 and MEK1/2 (Figure 4.13). 
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Interestingly the phosphorylation of p70S6K Thr389 was reduced quickly in comparison to 
EIF2S2 Ser2 and Akt Ser129. The phosphorylation of c-Raf Ser338,  
 
Figure 4.12 Differential Inhibition of mTOR Using CX-4945 and Inhibitor VIII 
HeLa cells were grown in media supplemented with FBS, followed treated with CX-4945, 
Inhibitor VIII, Torin1 or staurosporine for 240 minutes at indicated concentrations. Samples 
collected in this panel were collected in a RIPA lysis buffer. 
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Figure 4.13 Activation of the ERK MAPK Pathway in Reponse to CX-4945 is Rapid 
HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. Cells 
were then treated with CX-4945 for indicated time-points up to 180 minutes. All treatments 
were performed delivering drugs that were diluted in cell culture media without FBS 
supplementation. Samples collected in this panel were collected in  RIPA lysis buffer. 
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which contributes to the activity of c-Raf (182, 183), did not change in response to CX-4945 
within 180 minutes of treatment. c-Raf activity can also be regulated at Ser259 through 
phosphorylation by Akt, which is inhibitory as it can be sequestered by 14-3-3 proteins (184-
186) and can be de-phosphorylated by protein phosphatase 2A (PP2A) (187). In a follow-up 
experiment, HeLa cells were serum starved overnight followed by pre-treatment with or 
without PP2A inhibitor okadaic acid (1 µM) for 15 minutes followed by treatment with CX-
4945 to test if the phosphorylation status at c-Raf Ser259 could be contributing to MEK1/2 
and ERK1/2 activity (Figure 4.14). The phosphorylation status at Ser259 of c-Raf did not 
change in the presence or absence of okadaic acid when cells were treated with CX-4945, 
suggesting that the phosphorylation status of Ser338 and Ser259 on c-Raf is not a 
requirement for activation of MEK1/2 and ERK1/2 in response to CX-4945. The induction of 
ERK1/2 phosphorylation can be achieved in a span of 10 minutes of treatment with CX-4945 
or Inhibitor VIII and is nearly comparable to the induction observed using EGF within the 
same time (Supplemental Figure 4.14.1). Treatment with CX-4945 resulted in decreased 
phosphorylation of Akt Ser473 and Thr308, with pre-treatment using okadaic acid resulting 
in complete reduction of phosphorylation at these sites when treated with CX-4945 in 
comparison to cells that did not receive okadaic acid prior to CX-4945. 
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Figure 4.14 Activation of ERK MAPK is Independent of c-Raf Ser259  
HeLa cells were serum starved for 18 hours prior to treatment as noted in the figure. Cells 
were pre-treated with or without 1 µM okadaic acid for 15 minutes prior to treatment with 
CX-4945 at indicated time-points. All treatments were performed delivering drugs that were 
diluted in cell culture media without FBS supplementation. Samples collected in this panel 
were collected in a RIPA lysis buffer. 
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4.2.5 CX-4945 and Inhibitor VIII Affect Cell Cycle Regulation 
Previous phosphoproteomic analysis suggested an increase in CDK1 and CDK2 
activity in response to CX-4945 treatment, while identification of phosphopeptides enriched 
from MIB profiling suggested an increase in Tyr15 which results in an inhibition of CDK 
activity. To investigate this discrepancy, HeLa cells were arrested in specific phases of the 
cell cycle and analyzed using western blotting with antibodies against cell cycle markers in 
addition to profiling using flow cytometry (Figure 4.15, Supplemental Figure 4.44.4). 
Treatment with 20 µM CX-4945 did not result in an evident increase in Tyr15 
phosphorylation on CDK1 in comparison to DMSO after 240 minutes of treatment. 
Strikingly, treatment with 15 µM Inhibitor VIII resulted in increase phosphorylation of 
histone H3 Ser13 in comparison to either DMSO or CX-4945 within this period of time. This 
result is completely reversed upon longer treatment for 22 hours with either inhibitor, with 
complete abolishment of phospho-histone H3 Ser10 in cells treated with Inhibitor VIII. The 
increase in histone H3 Ser10 phosphorylation and total cyclin B1 suggests a G2/M phase 
arrest. Analysis using a two-colour method to analyze cell-cycle phase by flow cytometry 
(188) with the same clone for phospho-histone H3 Ser10 confirmed this result (Figure 4.16, 
Figure 4.17). Treatment of HeLa cells with CX-4945 for 4 hours results in an increase in G2 
specific cells in comparison to DMSO while the mitotic population remains similar. In 
contrast, Inhibitor VIII causes a 4x increase in the mitotic population. In agreement with the 
western blot analysis, long-term treatment with CX-4945 created a G2/M specific arrest, 
although there is a substantial amount of cells that are apoptotic (Figure 4.17). This apoptotic 
population is underestimated given the reliance on gating forward scatter and side scatter 
profiles of singlet  
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Figure 4.15 CX-4945 and Inhibitor VIII Perturb Cell Cycle Regulation 
HeLa cells were grown in media supplemented with FBS, followed treated with CX-4945, 
Inhibitor VIII, Torin1 or staurosporine for 240 minutes or 22 hours at indicated 
concentrations. In parallel HeLa cells were treated with lovastatin, mimosine, thymidine or 
nocodazole for 24 hours at indicated concentrations.  All treatments were performed by 
delivering drugs that were diluted in cell culture media without FBS supplementation. 
Samples collected in this panel were collected in a RIPA lysis buffer. 
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Figure 4.16 CX-4945 and Inhibitor VIII Exert Differential Effect on Histone H3 
Phosphorylation 
HeLa cells were grown in media supplemented with FBS, followed by treated with CX-4945, 
Inhibitor VIII, Torin1 or staurosporine for 240 minutes. Cells were processed for cell cycle 
analysis by flow cytometry, staining with 7-AAD, and antibodies against Ki-67 and phospho-
histone H3 Ser10, both conjugated to AlexaFluor-488. Gating was performed on forward and 
side scatter profiles to isolate single cells, and samples derived from HeLa cells arrested in 
specific phases of the cell cycle were used to appropriately gate cell populations presented. 
All treatments were performed delivering drugs that were diluted in cell culture media 
without FBS supplementation. 
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Figure 4.17 CX-4945 and Inhibitor VIII Result In Divergent Cell Cycle Arrest 
HeLa cells were grown in media supplemented with FBS, followed by treated with CX-4945, 
Inhibitor VIII, Torin1 or staurosporine for 22 hours. Cells were processed for cell cycle 
analysis by flow cytometry, staining with 7-AAD, and antibodies against Ki-67 and phospho-
histone H3 Ser10, both conjugated to AlexaFluor-488. Gating was performed on forward and 
side scatter profiles to isolate single cells, and samples derived from HeLa cells arrested in 
specific phases of the cell cycle were used to appropriately gate cell populations presented. 
All treatments were performed delivering drugs that were diluted in cell culture media 
without FBS supplementation. 
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cells within this assay which can occlude cells that have changed in shape and size as a result 
of undergoing apoptosis. Using a flow cytometry assay that directly measures cell viability 
using 7-AAD and annexin-V staining, 51% and 34% of HeLa cells treated with 20 µM CX-
4945 or 15 µM Inhibitor VIII respectively remain viable (Supplemental Figure 4.24.2).  
4.3 Discussion 
Investigation of the phosphoproteome presented previously in this thesis revealed a 
dynamic regulation of phosphoproteins in response to CX-4945 treatment in HeLa cells, 
suggesting a dynamic change in the activity of protein kinases responsible for 
phosphorylation of these substrates. MIBs allow the quantitative profiling of the kinome and 
have been utilized to study the effects of small-molecule ATP-competitive inhibition of 
kinases (84). To corroborate the putative regulation of kinases, we utilized two different 
inhibitor combinations for MIB profiling in order to monitor the kinase activity in extracts 
from HeLa cells treated with CX-4945 for 240 minutes.  
 The identification of the down-regulation of activity for kinases in the 
PI3K/Akt/mTOR pathways such as Sgk1, Akt and RPS6KB1 and the up-regulation of Ulk1 
activity validates the phosphoproteomic data presented earlier. The down-regulation of Sgk1, 
Akt and RPS6KB1 which are downstream of mTOR is in agreement with the literature which 
has identified CX-4945 treatment affecting Akt and mTOR activity (51, 54, 189). By 
comparison, the activity of mTOR as detected by MIB profiling did not appear to change 
using either MIB mix. One constituent that is regulated by mTOR, PKM, decreased in 
activity in response to CX-4945 and highlights a previously uncharacterized effect of this 
inhibitor with dramatic implications on metabolic regulation of glycolysis. CK2 has been 
implicated in regulation of metabolism, through the phosphorylation of phosphoglucose 
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isomerase (PGI) which is involved in glycolysis (190). A role in the regulation of the 
PI3K/Akt/mTOR pathways by CK2 has been previously implicated through the 
phosphorylation of phosphatase and tensin homolog (PTEN), which can stabilize the 
phosphatase preventing activity that is inhibitory towards the PI3K/Akt axis (191, 192). In a 
different investigation by So et al., treatment of cells with CX-4945 for extended periods of 
time in PC9 cells induced autophagy (193). LC3 can be used as a marker for autophagy, and 
when conjugated to phosphatidylethanolamine (denoted as LC3-II), it can be detected as a 
lower migrating band using SDS-PAGE/immuno-blotting (194). In contrast to the findings 
by So et al., experiments performed here used HeLa cells with initial western blotting failing 
to yield a clear difference in accumulation of LC3-II. When samples were collected using a 
denaturing buffer with NP-40 detergent, there was no apparent difference in LC3-II among 
samples treated with CX-4945, Inhibitor VIII or torin1. The presence of LC3-I (the higher 
migrating band) was slightly reduced with CX-4945 treatment in comparison to Inhibitor 
VIII and was comparable to treatment with torin1 or staurosporine. This may suggest an 
activation of autophagy as a result of mTOR inhibition, given that MIB profiling identified 
an increase in Ulk1 activity. Taking these details into perspective, it is interesting that when 
western blotting was performed using antibodies against phospho-4E-BP1 in lysates derived 
from HeLa cells that were treated with two unrelated inhibitors of CK2, a differential effect 
in the level of phosphorylation was noted between CX-4945 and Inhibitor VIII treatment. 
Both CK2 inhibitors reduced the phosphorylation level of EIF2S2, confirming inhibition of 
CK2 by both inhibitors and suggesting a potential divergence in the specificity between these 
two inhibitors when investigating the PI3K/Akt/mTOR pathway.   
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The intersection of the PI3K/Akt/mTOR and MAPK pathways has been previously proposed 
(as reviewed in (195)). Treatment with CX-4945 resulted in the activation of kinases that 
comprise the ERK MAPK pathway, with increased phosphorylation of ERK1/2, MEK1/2, 
and p90-RSK as quantified using MIB profiling. CK2-dependent inhibition is suggested as a 
potential mechanism given that two unrelated inhibitors of CK2 result in increased 
phosphorylation of ERK1/2 Thr202/Tyr204. This effect was determined to be independent of 
p38 MAPK activation, as treatment with either CK2 inhibitor did not result in 
phosphorylation of p38 MAPK. Interestingly, the activity of IRAK1 increased in response to 
CX-4945, and it has been documented that IRAK1 activation can lead to p38 MAPK 
activation dependent on Ras activation (196). The phosphorylation status of Ser259 on c-Raf 
did not change in this context, suggesting that the intersection of the PI3K/Akt pathway does 
not regulate this arm of the MAPK pathway. The activity of IRAK1 upstream of Ras 
suggests this pathway could still be activating c-Raf, given that other phosphorylation sites 
on c-Raf that modulate activity were not profiled. Previous investigation of CK2 in 
glioblastoma cells highlighted the activation of ERK in response to CK2 knockdown in the 
presence or absence of neocarzinostatin, although the presence of neocarzinostatin 
substantially enchanced ERK phosphorylation (197). The results presented here support the 
activation of the ERK MAPK pathway when cells are treated with CX-4945 or Inhibitor 
VIII, suggesting a CK2-dependent role in this manner. In contrast to this, more recent studies 
conducted in melanoma cell lines identified a CK2-dependent role for proteasomal 
degradation of dual specificity phosphatase-6 (DUSP6), which can reverse the activating 
phosphorylation on ERK mediated by MEK (198). Knock-down of CK2α resulted in 
increased levels of DUSP6, while high expression of CK2α maintained ERK 
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phosphorylation. A cell-line dependent effect may be plausible for the differences 
documented in terms of ERK phosphorylation, warranting further investigation.  Despite 
apparent cell type specific contexts, these observations all suggest that CK2 can modulate the 
ERK MAPK pathway. 
 The identification of CDK phosphorylation at Tyr15 using MIB profiling suggested 
that in response to CX-4945 treatment HeLa cells undergo cell cycle arrest. The 
phosphorylation at Tyr15 is well known to inhibit the activity of CDK1 (178). In contrast, the 
phosphoproteomic investigation revealed that CDK1 and CDK2 substrates increased in 
phosphorylation in response to CX-4945 suggesting a progression in cell cycle from G2 to M 
phase. Western blotting and flow cytometry analysis were performed to investigate this 
difference. In agreement with the existing literature, CX-4945 treatment resulted in a G2/M 
accumulation during longer periods of treatment (44, 45). Shorter treatment of 240 minutes 
saw an increase in the G2 population in comparison to DMSO, suggesting cell cycle arrest 
occurred rapidly. These effects were not evident by western blotting at shorter time-points 
given that the markers used were specific for identifying the mitotic phase. Remarkably, 
treatment with Inhibitor VIII increased the phosphorylation of histone H3 Ser10 at 240 
minutes but abolished it completely at 22 hours. One possible hypothesis is that treatment 
with this inhibitor drives cell cycle progression into mitosis, given that reports of histone H3 
Ser10 phosphorylation as a result MAPK activation have been documented (199). The 
increase in mitotic phase cells was not as pronounced with CX-4945 treatment, and given the 
complete abolishment of histone H3 Ser10 phosphorylation at 22 hours of treatment with 
Inhibitor VIII, the specific reason for why histone H3 Ser10 phosphorylation occurs is 
difficult to reconcile without further investigation. Inhibitor VIII may exert a stimulatory 
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effect upon the kinase responsible for phosphorylation of histone H3 Ser10, Aurora B kinase 
(200, 201), or it may antagonize phosphatase activity towards this site (202, 203). This 
previously undocumented divergence between Inhibitor VIII and CX-4945 further calls into 
question the specificity of these CK2 inhibitors given differential outcomes in the 
phosphorylation status of proteins involved in distinct cellular processes.  
 Kinome profiling using MIBs enabled the characterization of kinase activity and 
validation of phosphoproteomic profiling of HeLa cells treated with CX-4945. A broad effect 
on kinase activity was documented, corroborating changes in the activity of kinases as 
inferred by phosphoproteomic analysis of HeLa cells treated with CX-4945 in earlier 
investigations in this thesis. Taken together, the analysis of the kinome and phosphoproteome 
identify CK2-dependent and CK2-independent effects in HeLa cells. Utilization of a different 
CK2 inhibitor further substantiates CK2-independent effects of CX-4945, as suggested by the 
incomplete overlap between the cellular effects of CX-4945 and Inhibitor VIII. These 
revelations call into question the utility of CX-4945 as an inhibitor of CK2 to study putative 
CK2-dependent processes in cells and warrant future studies to characterize putative CK2-
independent effects.  
4.4 Experimental Methods 
4.4.1 Cell Culture and Lysis for Multiplexed Inhibitor Bead Profiling 
SILAC-dropout DMEM (Life Technologies) supplemented with light and heavy isotope-
encoded L-arginine and L-lysine was prepared as previously described in Chapter 3.4.2.  
HeLa Tet-Off cells that were previously adapted in SILAC media were grown in 15 cm 
dishes. Three biological replicates (consisting of three independent cell culture plates 
harvested on the same day) of heavy labeled cells were treated with 20 µM CX-4945 
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(MedKoo Biosciences) for 240 minutes with light labeled cells being treated with DMSO. In 
a “label-swap experiment” one biological replicate was used where the heavy labeled cells 
were treated with DMSO and the light labeled cells were treated with 20 µM CX-4945. Cells 
were rinsed with ice-cold PBS and lysed in MIB lysis buffer [0.5% Triton X-100 (Sigma), 50 
mM (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (HEPES) pH 7.5 (Bioshop), 1 mM 
EDTA, 1 mM EGTA, 10 mM sodium fluoride, 1 µM microcystin-LR, 2.5 mM sodium 
orthovanadate, pepstatin (2.0 µg/mL), 0.2 mM phenylmethylsulfonyl fluoride (PMSF), 
leupeptin (20 µg/mL), aprotinin (4 µg/mL), and 1x phosphatase inhibitor cocktail 2 & 3 
(Sigma P5726, P0044)]. Samples were sonicated for 3 x 10 seconds on ice then spun for 10 
minutes at 16,000 x g at 4 °C. The supernatant was collected and clarified once more using a 
0.2 µm syringe filter and protein concentration was determined by Bradford Assay (Bio Rad) 
before being stored at -80 °C until further processing. Aliquots of samples were diluted in 
sample loading buffer and 10 µg of sample was loaded per lane and separated by SDS-
PAGE. Proteins were transferred to PVDF membrane (Millipore) using a wet-transfer 
apparatus (Bio-Rad) at 400 mA for 60 minutes at 4 °C followed by block in blocking buffer 
(LI-COR Biosciences) for 60 minutes. Primary antibodies were incubated overnight at 4 °C 
in 3% BSA-TBST or 3% BSA-PBST. Antibodies against GAPDH (MAB374, Millipore) and 
pEIF2S2 S2 (YenZym Laboratories, raised against ac-pS-GDEMIFDPTMSKC-amide) were 
used. Secondary antibodies used were GAR-800 (926-32211), GAM-800 (926-32210), and 
GAM-680 (926-32220) (LI-COR Biosciences) in 3% BSA-TBST or 3% BSA-PBST, with 
incubation for 45 minutes. Membranes were scanned using an Odyssey scanner (LI-COR 
Biosciences) at 700 nm and 800 nm wavelengths. Raw data scans were loaded into 
ImageStudioLite v5.2.5 (LI-COR Biosciences) and exported as .TIFF image files.  
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4.4.2 Multiplexed Inhibitor Bead Profiling Using a 6-Inhibitor Mix 
MIB profiling of SILAC-labelled HeLa cells treated with CX-4945 was adapted from the 
protocol that was previously described by Qin et al (171). The MIB mix utilized was a 
generous gift from Dr. Lee M. Graves at the University of North Carolina, Chapel Hill, NC, 
and consisted of six kinase inhibitors each conjugated to ECH sepharose 4B: Shokat (204), 
PP58 (205, 206), VI16832 (83), Ctx-0294885 (207), purvalanol-B (208), and pan-Akt 
inhibitor UNC21474 (171). Chemical structures of these kinase inhibitors are displayed in 
Supplemental Figure 4.5. Equivalent amounts (2.5 mg) of heavy and light SILAC lysates 
were brought to 1M NaCl and equalized for volume prior to mixing. Samples were first 
passed over a column (Bio-Rad) containing ECH sepharose 4B, followed by passage over a 
column containing MIBs. MIB columns were then washed with 5 mL MIB lysis buffer 
containing 1M NaCl, followed by 5 mL MIB lysis buffer and 0.5 mL MIB lysis buffer 
containing 0.1% (w/v) SDS. Captured proteins were eluted twice with 0.5 mL [0.5% (w/v) 
SDS, 1% beta-mercaptoethanol, 100 mM Tris-HCl pH 6.8] by incubating at 95 °C for 15 
minutes. Samples were then reduced with 5 mM DTT (Sigma) for 25 minutes at 60 °C, 
alkylated with 20 mM IAA (Sigma) for 30 minutes at room temperature in the dark and 
quenched with the addition of 10 mM DTT. Samples were then concentrated using 0.5 mL 
10 kDa-cutoff spin filters (Millipore) and reduced to approximately 100 µL of volume. 
Samples were precipitated following chloroform (Sigma) and methanol (Fisher) extraction, 
using methanol, chloroform and water at a ratio of 4:1, 1:1 and 3:1 respectively to sample 
volume. Precipitated protein was pelleted by centrifugation at 16, 000 x g for 10 minutes 
followed by two washes with 0.5 mL of methanol. Pellets were digested using 1 µg trypsin-
Lys-C (Promega) for 4 hours at 37 °C and topped up with 1 µg trypsin (Pierce) for overnight 
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digestion in 50 mM ammonium bicarbonate. Samples were then desalted using C18 
StageTips, concentrated in a SpeedVac vacuum centrifuge and stored at -80 °C until LC-
MS/MS analysis. 
4.4.3 Multiplexed Inhibitor Bead Profiling Using a 4-Inhibitor Mix 
MIB profiling of SILAC-labelled HeLa cells treated with CX-4945 was performed as 
previously described in Kurimchak et al. (172) and followed procedures similar to that used 
with the 6-Inhibitor mix. The MIB mix utilized was a generous gift from Dr. James S. 
Duncan at Fox Chase Cancer Center, Philadelphia, PA, and consisted of four inhibitors: PP58 
(205, 206), VI16832 (83), Ctx-0294885 (207) and purvalanol-B (208).  Heavy and light 
SILAC-labelled lysates (3-5 mg) were brought to 1M NaCl and equalized for volume prior to 
mixing. Samples were first passed over a column (Bio-Rad) containing beads conjugated 
with inhibitors PP-58, VI-16832 and purvalanol-B, followed by passage over a second 
column containing Ctx-0294885. MIB columns were then washed separately with 2 x 10 mL 
MIB lysis buffer containing 1M NaCl, followed by 10 mL MIB lysis buffer. Samples were 
then eluted from each column and combined prior to concentration. All subsequent steps in 
sample preparation followed the 6-Inhibitor mix procedure outlined in section 4.4.2. 
4.4.4 LC-MS/MS Analysis of Samples Profiled by Multiplexed Inhibitor Beads 
Samples were analyzed using an Orbitrap Elite Hybrid Ion Trap-Orbitrap mass spectrometer 
using the acquisition parameters and settings previously described in Chapter 2.4.10. 
Biological replicates were each analyzed in technical duplicate. Raw mass spectra files were 
analyzed in MaxQuant version 1.5.3.8 (70, 71, 164) and searched against the Swissprot-
Uniprot sequence database (homo sapiens taxon, accessed on December 26, 2015). Samples 
were searched using a Multiplicity set to 2, with “heavy” labels selected as Arg6 and Lys4. 
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Mass tolerances were set to 4.5 ppm for the parent ion mass (MS) and 0.5 Da for the 
fragment ion mass (MS/MS). The minimum number of amino acids in a peptide was set to 7, 
with a peptide spectrum match (PSM) and protein match set to 1% FDR and protease 
selectivity for trypsin/P. A maximum number of 3 missed cleavages was selected. The option 
for second peptide search was selected, as was the use of “Match Between Runs” for 
respective pairs of samples between biological replicates, using the default matching 
parameters. Raw mass spectra files were defined as separate groups using the experimental 
setup option. Cysteine carbamidomethylation (+ 57.0215 Da) was set as a fixed modification. 
The number of variable modifications per peptide was 5, with methionine oxidation 
(+15.9949 Da), protein N-terminus acetylation (+42.0105 Da), asparagine and glutamine 
deamidation (+0.9840 Da) and serine, threonine, and tyrosine phosphorylation (+79.9663) 
selected. The minimum score for modified peptides was set to 40, and the decoy-database 
setting was “Revert.” For quantitation of protein groups, unmodified peptides and those with 
carbamidomethylation, methionine oxidation, protein N-terminus acetylation or asparagine 
and glutamine deamidation were included. Peptides for which the corresponding heavy or 
light modified peptide was not quantified were excluded from the protein groups 
quantitation. Output data from MaxQuant was then loaded into Perseus version 1.5.2.6 (121). 
For the analysis of proteome data, the “proteinGroups.txt” file was first processed to remove 
entries marked as reverse decoy database hits, contaminants, and protein identifications that 
were only matched to modified peptides. MaxQuant-generated normalized ratios were 
utilized, and the log base 2 of the normalized ratios was calculated for each protein. Proteins 
were considered identified in each biological replicate if identified in at least one of two 
technical replicates. For the analysis of the phosphoproteome data, the “Phospho 
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(STY)Sites.txt” file was first processed to remove entries marked as reverse decoy database 
hit and contaminants, and filtered to only contain phosphorylation sites with localization 
probability greater than 0.75. Phosphorylation sites were expanded in Perseus to obtain 
information from instances of quantified sites being derived from singly, doubly and triply-
phosphorylated peptides. Rows where no quantification was present were removed, and 
phosphorylation sites were considered quantified in each biological replicate if they were 
identified in at least one of two technical replicates.  
4.4.5 Cell Culture and Lysis for Analysis of mTOR/Akt and MAPK Pathways 
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100 
µg/mL) on 10 cm dishes or in 6-well plates. Cells were either grown in media containing 
10% FBS or were serum starved for 18 hours prior to treatment with inhibitors. Cells were 
treated with 20 µM CX-4945 (MedKoo Biosciences), 15 µM Inhibitor VIII (Calbiochem), 
0.25 µM Torin1 (Selleckchem), 1 µM MG-132 (Sigma), 20 ng/mL neocarzinostatin (Sigma), 
2 µM staurosporine (LC Laboratories) or DMSO diluted in media without FBS for indicated 
time-points. Cells were rinsed with PBS on ice prior to lysis. For experiments used to 
generate Figures 4.10-4.11, HeLa cells were lysed in MIB lysis buffer that is described in 
section 4.4.1. For all remaining experiments, HeLa cells were lysed in a RIPA lysis buffer 
[1% NP-40 Alternative (Calbiochem), 50 mM Tris pH 7.5, 150 mM sodium chloride 0.5% 
sodium deoxycholate (Sigma), 0.2% SDS, 1 mM EDTA, 25 mM β-glycerophosphate, 1 µM 
okadaic acid, 50 mM sodium fluoride, 1 µM microcystin-LR, 10 mM sodium orthovanadate, 
5 mM sodium pyrophosphate, pepstatin (10 µg/mL), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), leupeptin (100 µg/mL), and aprotinin (20 µg/mL)]. Samples were sonicated for 2 x 
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15 seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C, upon which the supernatant 
was retained and protein concentration was determined using a BCA assay (Pierce). Samples 
(10 µg each) were separated by SDS-PAGE and transferred to PVDF membranes for Western 
blotting using procedures outlined in Chapter 4.4.1.  Antibodies against phospho-p90RSK 
S380 (9335), p90RSK (9355), phospho-ERK1/2 T202/Y204 (9106), ERK (9102), phospho-
MEK1/2 S217/221 (9154), MEK1/2 (4694), phospho-p38 MAPK T180/Y182 (9216), p38 
MAPK (8690), phospho-Akt T308 (13038), phospho-Akt S473 (4060), phospho-c-Raf S338 
(9427), phospho-c-Raf S259 (9421), phospho-mTOR S2448 (5536), mTOR (2983), LC3B 
(3868), phospho-Raptor S792 (2089), phospho-Ulk1 S638 (14205), p70S6K T389 (9234),  
PARP (9542), phospho-4E-BP1 T37/46 (2855) (all from Cell Signaling Technologies), 
hVIN1 (V9131, Sigma), γH2AX S139 (ab26350, Abcam), phospho-Akt S129 (ab133458, 
Abcam), GAPDH (MAB374, Millipore), and phospho-EIF2S2 S2 (YenZym Laboratories, 
raised against ac-pS-GDEMIFDPTMSKC-amide) were used. 
4.4.6 Cell Culture and Sample Preparation for Cell Cycle Analysis using Flow 
Cytometry and Western Blotting 
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100 
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945 (MedKoo Biosciences), 15 
µM Casein Kinase II Inhibitor VIII (Calbiochem), 0.25 µM Torin1 (Selleckchem) or DMSO 
for 240 minutes or 22 hours. In parallel, cells were treated with 40 µM lovastatin (Sigma-
Aldrich), 400 µM mimosine (Sigma-Aldrich), 2 mM thymidine (Sigma-Aldrich), nocodazole 
(0.4 µg/mL) (Sigma-Aldrich) or were serum-starved for 24 hours to generate arrested 
populations to aid in the setting of cell-cycle specific gated populations for flow cytometry 
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and for the comparison by Western blotting using cell-cycle markers. After treatment, media 
was retained and adherent cells were washed with PBS, then incubated with 0.25% trypsin, 
0.02% EDTA solution at 37 °C to lift the cells. Cells were suspended in collected media, 
centrifuged at 100 x g then suspended in fresh serum-free DMEM. An aliquot was stained 
with 0.08% trypan blue solution (Sigma-Aldrich) and the concentration of cells was 
determined using a hemocytometer. Aliquots of 1 million cells were centrifuged at 100 x g 
and washed with PBS. For Western blotting, cell pellets were lysed in 300 µL lysis buffer 
[1% NP-40 Alternative (Calbiochem), 50 mM Tris pH 7.5, 150 mM sodium chloride 0.5% 
sodium deoxycholate (Sigma), 0.2% SDS, 1 mM EDTA, 25 mM β-glycerophosphate, 1 µM 
okadaic acid, 50 mM sodium fluoride, 1 µM microcystin-LR, 10 mM sodium orthovanadate, 
5 mM sodium pyrophosphate, pepstatin (10 µg/mL), 1 mM phenylmethylsulfonyl fluoride 
(PMSF), leupeptin (100 µg/mL), and aprotinin (20 µg/mL)]. Samples were sonicated for 2 x 
15 seconds on ice then spun for 10 minutes at 16,000 x g at 4 °C, upon which the supernatant 
was retained and protein concentration was determined using a BCA assay (Pierce). Samples 
(10 µg each) were separated by SDS-PAGE and transferred to PVDF membranes for Western 
blotting using procedures outlined in Chapter 4.4.1. 
Antibodies against phospho-histone H3 S10 (9542), histone H3 (9715), cyclin B1 (12231), -
phospho-cdc2 Y15 (4539), phospho-4EBP1 T37/46 (2855) (all from Cell Signaling 
Technologies), γH2AX S139 (ab26350, Abcam), GAPDH (MAB374, Millipore), and 
phospho-EIF2S2 S2 (YenZym Laboratories, raised against ac-pS-GDEMIFDPTMSKC-
amide) were used. For flow cytometry analysis, samples were processed as previously 
described in Vignon et al. (188) with some modifications. Cell pellets were suspended in 1 
mL PBS and added drop-wise to 5 mL of ice cold 95% ethanol with agitation between drop-
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wise addition then fixed overnight at – 20 °C. Samples were centrifuged at 500 x g for 5 
minutes at room temperature, followed by aspiration of ethanol and suspended in PBS before 
being transferred to FACS tubes. Samples were then washed twice with 3 mL PBS, followed 
by two washes with 1 mL 0.25% Triton X-100, 1% FBS in PBS (PFT). Samples were stained 
in 200 µL of PFT for 30 minutes in the dark, after being mixed with 15 µg of 7-
aminoactinomycin (7-AAD) (A1310, Thermo Scientific), 3 µL of anti-phospho-histone H3 
Ser10 conjugated to AlexaFluor-488 (3465, Cell Signaling Technology), and 3 µL of anti-
Ki67 conjugated to AlexaFluor-488 (11882, Cell Signaling Technology). Single stain and 
iso-type controls were processed in parallel. Samples were then washed twice with 1 mL PFT 
and once with 1mL PBS. Cells were analyzed on a Becton Dickinson FACSCanto cytometer 
using FACSDiva software, acquiring 10,000 cell events per sample. Data generated were 
analyzed using FLOWJo software v10.2 (FLOWJo, LLC, Ashland, Oregon), gating 
populations according to forward and side scatter profiles and setting cell-cycle specific 
populations according to positive control populations arrested in specific phases of the cell 
cycle.  
4.4.7 Cell Culture and Sample Preparation for Cell Viability Analysis using Flow 
Cytometry 
HeLa Tet-Off cells (Clontech) were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) (Corning) containing 10 % FBS, penicillin (100 U/mL) and streptomycin (100 
µg/mL) on 10 cm dishes. Cells were treated with 20 µM CX-4945, 15 µM Casein Kinase II 
Inhibitor VIII, or DMSO for 240 minutes or 22 hours. In parallel, cells were treated with 2 
µM staurosporine as a positive control for gating live and dead cell populations. After 
treatment, media was retained and adherent cells were washed with PBS, then incubated with 
  
142 
0.25% trypsin, 0.02% EDTA solution at 37 °C to lift the cells. Cells were suspended in 
collected media, centrifuged at 500 x g then suspended in warm 5% FBS in PBS. An aliquot 
was stained with 0.08% trypan blue solution (Sigma-Aldrich) and the concentration of cells 
was determined using a hemocytometer. 100,000 cells were aliquoted into FACS tubes, 
centrifuged at 100 x g and suspended in 200 µL Annexin V binding buffer (Biolegend). 4 µL 
of anti-annexin-V conjugated to Brilliant Violet 421 (640923, Biolegend) was added to the 
sample and incubated in the dark for 15 minutes. Single colour and unstained live and dead 
cell populations were processed as well. Samples were then diluted with 1 mL of 5% FBS in 
PBS and centrifuged at 500 x g. The volume was reduced to approximately 200 µL by 
vacuum aspiration and 4 µL of 7-AAD solution (420404, Biolegend) was added prior to 
analysis on a Becton Dickinson FACSCanto cytometer using FACSDiva software, acquiring 
10,000 cell events per sample. Data generated were analyzed using FLOWJo software v10.2 
(FLOWJo, LLC, Ashland, Oregon), gating populations according to forward and side scatter 
profiles and setting live and dead specific populations according to positive control 
populations and single colour stains. 
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4.5 Supplemental 
 
Supplemental Figure 4.1 CX-4945 and Inhibitor VIII Stimulate ERK1/2 
Phosphorylation 
HeLa cells were serum starved for 18 hours prior to treatment with EGF, CX-4945, Inhibitor 
VIII or DMSO at indicated concentrations for 10 minutes. 
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Supplemental Figure 4.2 Cell Viability of HeLa Cells Treated with CX-4945 and 
Inhibitor VIII 
HeLa cells were grown in media supplemented with FBS, followed by treatment with CX-
4945, Inhibitor VIII, Torin1 or staurosporine for 4 or 22 hours.  Cells were processed for cell 
viability analysis by flow cytometry, staining with 7-AAD, and an antibody against annexin-
V conjugated to BV-421. Non-viable cells are located in quadrant Q2. 
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Supplemental Figure 4.3 Cell Viability of HeLa Cells Treated with DMSO 
HeLa cells were grown in media supplemented with FBS, followed by treatment with DMSO 
for 22 hours.  Cells were processed for cell viability analysis by flow cytometry, staining 
with 7-AAD, and an antibody against annexin-V conjugated to BV-421. 
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Supplemental Figure 4.4 HeLa Cells Arrested in Specific Phases of Cell Cycle 
HeLa cells were treated with lovastatin, mimosine, thymidine or nocodazole for 24 hours. 
Cells were processed for cell cycle analysis by flow cytometry, staining with 7-AAD, and 
antibodies against Ki-67 and phospho-histone H3 Ser10, both conjugated to AlexaFluor-488. 
Gating was performed on forward and side scatter profiles to isolate single cells. 
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Supplemental Figure 4.5 Chemical Structures of Multiplexed Inhibitor Beads 
 
  
148 
 
5 Chapter 5 – Discussion 
5.1 Introduction 
The phosphorylation of proteins at serine, threonine and tyrosine residues is a critical 
post-translational modification involved in the transmission of regulatory signals that control 
cellular homeostasis. The addition of phosphate to these phospho-acceptor amino acid 
residues is mediated by protein kinases in eukaryotes. Expectedly, deregulation of kinase 
activity can contribute to aberrant signaling processes implicating kinases in the progression 
of diseases such as cancer (8). The work presented in this thesis has been focused on protein 
kinase CK2, a small family of enzymes that has been traditionally classified as 
serine/threonine specific but also demonstrated to be capable of phosphorylating tyrosine 
residues (209). Considering the number of proteins that are phosphorylated by CK2 
implicating it in the regulation of several pathways (15), and its deregulated expression in 
several different types of human cancer (14), CK2 has emerged as a therapeutic target.  In 
fact, an orally bioavailable small molecule ATP-competitive inhibitor of CK2, CX-4945, has 
recently progressed into clinical trial (44). Given the emergence of CK2 as a therapeutic 
target, the goal of this thesis was to utilize a mass-spectrometry based proteomics approach 
to perform unbiased profiling of CX-4945. This approach enabled the identification of 
dynamic markers of CK2 inhibition and CK2-dependent processes in cells treated with CX-
4945, as well as revealing potential CK2-independent effects of CX-4945. 
5.2 Summary of Research Contributions 
5.2.1 Development of a Phosphoproteomic Workflow 
Prior to directly undertaking a phosphoproteomics approach to characterize the 
effects of CX-4945 in HeLa cells, a comparative investigation of sample preparation methods 
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was performed in order to determine an optimized phosphoproteomics workflow. 
Conventional phopshoproteomic strategies typically take advantage of large-scale 
fractionation methods such as strong-cation exchange chromatography to increase the 
enrichment of lower abundance phosphopeptides (96). With recent advances in mass 
spectrometry, strategies for phosphopeptide enrichment that do not require fractionation have 
also been developed and have been documented to perform comparably to fractionation 
approaches such as strong cation exchange chromatography (108). In chapter 2, comparison 
of strategies for phosphopeptide enrichment performed both with and without fractionation 
by strong cation exchange demonstrated that the two approaches were comparable in 
phosphopeptide identification. By comparing different sorbents for sample desalting, I 
observed that using porous graphitic carbon for sample desalting resulted in an enrichment of 
phosphopeptides that contained a CK2 consensus motif. Considering that the amino acid 
specificity determinants for CK2 can render a peptide sequence hydrophilic in nature (92-
95), matching a sorbent such as porous graphitic carbon which is selective for polar 
compounds enables better identification of CK2 phosphopeptides than using a reverse-phase 
C18 sorbent. Another recent development in a phosphopeptide enrichment protocol termed 
“EasyPhos” utilizes a digestion buffer compatible with phosphopeptide enrichment thereby 
omitting desalting prior to enrichment, and takes advantage of mixed-mode styrene-divinyl-
benzene reverse phase sulfonate sorbent (SDB-RPS) for desalting prior to LC-MS/MS 
analysis (210). This results in a simplified format omitting steps which can incur sample loss 
normally observed with desalting, reducing the amount of protein sample required for 
enrichment and enabling the retention of hydrophilic phosphopeptides for LC-MS/MS. 
Considerations in tailoring sorbents and protocols for enrichment of target analyte can 
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enhance contextual biological information in proteomic investigations of interest. The 
comparison of porous graphitic carbon to C18 solid phase extraction columns for peptide 
desalting demonstrates the utility of hydrophilic sorbent in analyzing phosphopeptides 
derived from CK2 substrates.  
The investigation of proteome preparation revealed advantages in using protein 
precipitation in comparison to filter-aided sample preparation for the generation of proteomes 
for subsequent phosphopeptide enrichment. Although both preparation methods identified 
nearly the same number of proteins, protein precipitation yielded more phosphorylation sites. 
In this thesis protein precipitation was performed using TCA and acetone overnight at -20 
°C. However other protein precipitation protocols such as chloroform/methanol (211) which 
can be done within the span of one hour could be used in order to reduce sample processing 
time.  
In summary, when considering the evaluation of CK2 phosphopeptides by mass 
spectrometry it is necessary to tailor sorbents and materials to match the unique determinants 
that render the substrates of CK2 hydrophilic. It was demonstrated that using porous 
graphitic carbon could enrich for phosphopeptides conforming to the CK2 consensus 
sequence. In considering the practical aspects of profiling the phosphoproteome, sample 
handling and instrument time are reduced when utilizing an unfractionated strategy. This 
resulted in similar rates of protein and phosphorylation site identification. Furthermore, 
comparative analysis of proteome sample preparation strategies identified that protein 
precipitation of samples coupled with two-step C18 and porous graphitic carbon peptide 
desalting in combination with phosphopeptide enrichment enables the identification of a 
maximum number of proteins and phosphorylation sites in a timely manner. Taken together, 
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these results demonstrate the utility of an unfractionated phosphoproteomics tailored with 
hydrophilic sorbents that should be employed when analyzing CK2 phosphopeptides. 
5.3 Unbiased Proteomic Characterization of CX-4945 
5.3.1 CX-4945 Results in a Dynamic Phosphoproteome 
CX-4945 represents the first clinical stage ATP-competitive inhibitor of CK2 to 
progress into clinical trial. Despite the advances of CX-4945 in therapeutic applications and 
widespread utilization as the “gold standard” CK2 inhibitor in the research community, it is 
unclear how its effects are rendered in cells.  A systematic quantitative phosphoproteomic 
approach was undertaken utilizing SILAC labeled cells to characterize the impact of CX-
4945 treatment in HeLa cells following the optimization of a phosphoproteomics workflow 
tailored to identify phosphopeptides derived from CK2 substrates. This approach enabled the 
identification of phosphorylation sites indicating CK2 inhibition that exhibited dynamic de-
phosphorylation over a period of 240 minutes. Several of these sites displayed a magnitude 
of change that was greater than that of EIF2S2 Ser2, a bona fide substrate of CK2 that has 
been previously exploited to monitor CK2 inhibition in cells. This included the identification 
of topo-isomerase II alpha (TOP2A) Ser1377 and presents an opportunity to use this 
phosphorylation site as an indicator of CK2 inhibition in cells. Furthermore, identification of 
differential de-phosphorylation on EIF2S2 at Ser2 and Thr111 in response to CX-4945 
highlights a previously underappreciated role of phosphatase activity towards CK2 
phosphorylation sites on the same protein.  
Overall, analysis of CK2 phosphorylation sites that decreased in response to CX-4945 
utilizing gene set enrichment analysis identified biological processes involved in DNA repair 
and translation. Previous studies have also highlighted the role that CK2 plays in regulating 
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proteins that are components of these processes (29, 212). Collectively, these findings 
suggest that these biological processes may be representative of the most critical pathways 
involved in the maintenance of cellular homeostasis that are first affected upon inhibition of 
CK2.  
The phosphoproteomics approach presented in chapter 3 also enabled the profiling of 
phosphorylation sites attributed to other kinases that were revealed using kinase substrate 
enrichment analysis. Inhibition of CK2 may lead to the indirect regulation of other kinases in 
the cell. There is precedence for the regulation of kinases through the activity of CK2 
towards the phosphorylation of cdc37 Ser13, a kinase co-chaperone (136). Interestingly, 
treatment with CX-4945 within the period of time up to 240 minutes affected several other 
kinases such as Akt1 and mTOR as concluded by the phosphorylation status of target 
substrates.  
MIB profiling was performed in order to investigate whether changes observed in the 
phosphoproteomic profiling would correlate with the change in activity of the respective 
upstream kinases. Indeed when this investigation was followed up, kinases in the 
PI3K/Akt/mTOR pathways were affected by CX-4945. Although the quantification of 
activity in mTOR did not change drastically as well as CK2, other kinases that are 
downstream of mTOR such as Akt1, Sgk1 and Ulk1 changed in activity suggesting mTOR 
inhibition.  
5.3.2 Limitations of Profiling Effects of CX-4945 in HeLa Cells Using MIBs 
One potential limitation in using MIBs to determine the activity of kinases that are 
targets of CX-4945 in cells is that the residual amount of CX-4945 in the lysate that could 
interfere with the ability of kinases to bind to the MIBs. Considering that the protein extracts 
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from treated and untreated samples are mixed 1:1 prior to MIB profiling, residual CX-4945 
from the treated samples may interfere with the CK2 catalytic subunits derived from cells 
that were treated with DMSO. Consequently, this may also impact the putative off-targets of 
CX-4945, thus explaining why regulation of mTOR was not apparent although downstream 
targets were quantified. 
Another limitation may relate to the composition of the inhibitor mix used for profiling. 
In this respect, a recent investigation of kinase activity profiling methods such as MIBs 
identified cases where capture of kinases by MIBs was independent of kinase activity (213). 
The MIB strategy by Duncan et al. (84) is intended to isolate the active kinome. Ruprecht et 
al. (214) noted that the type inhibitor mix used could affect the conformation-dependent 
binding. On a related note, determining which variable modifications are included for 
peptides derived from kinases that are used for quantification may also obscure the activity of 
a kinase by MIB profiling. Typically peptides with variable modifications that could play a 
regulatory role are excluded in the quantitation at the protein level, and only modifications 
that result because of sample handling, as in the case of methionine oxidation are included in 
such searches. This was the case for ERK1/2 where the quantification at the protein level 
revealed no apparent change but the phosphorylation status of Thr202/Tyr204 and 
Thr185/Tyr187 increased. In these analyses, peptides with phosphorylation as a variable 
modification were excluded in the calculation of protein abundance considering it was 
unknown beforehand whether phosphorylation sites on kinases which change but do not 
confer activation status could result in quantification unrepresentative of biochemical 
function. Despite this limitation, utilizing the phosphorylation specific data collected in these 
experiments still enabled investigation of kinase activity. Efforts to overcome the limitations 
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of affinity-capture strategies, such as MIBs for profiling the active kinome, represent an 
active area of investigation. In this respect, a very recent study presented an optimized MIB 
mix using 12 different inhibitors that when coupled with improvements in liquid 
chromatography using monolithic columns and targeted mass spectrometry enabled the 
reliable quantification of active kinases (215).  Looking to the future, it can be expected that 
further technological developments in this field will improve the systematic quantification of 
kinase activity by MIB profiling.  
5.3.3 Differential Effects of CX-4945 and Inhibitor VIII in HeLa cells 
The phosphoproteomic and kinome profiling suggested that mTOR was also affected in 
addition to inhibition of CK2. By comparison, treatment of HeLa cells with an unrelated 
inhibitor, “Inhibitor VIII” identified a differential effect upon the PI3K/Akt/mTOR pathway 
in contrast to CX-4945, with both inhibitors displaying a decrease in phosphorylation of 
EIF2S2 Ser2.  This result suggests that CX-4945 is also a putative inhibitor of mTOR in 
HeLa cells and warrants further investigation. This contrasted to the observation that both 
Inhibitor VIII and CX-4945 treatment resulted in activation of the ERK MAPK pathway. 
Interestingly, when cell cycle analysis was performed by flow cytometry, CX-4945 and 
Inhibitor VIII treatment also resulted in distinct effects on phospho-histone H3 Ser10. 
Collectively, these results raise questions about the specificity of these CK2 inhibitors and 
emphasize the need for systematic characterization of kinase inhibitors to both validate 
inhibition of the intended target and identify potential downstream effects of target inhibition 
or potential off-targets. Furthermore, the results presented in this thesis highlight the 
underappreciated complexity of the phosphoproteome when challenged with CX-4945, 
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which has been used extensively as the “gold standard” CK2 inhibitor given its emergence in 
ongoing clinical trial. 
5.4 Future Directions 
5.4.1 Characterization of CK2-independent Effects of CX-4945 in cells 
Given the utility of small molecule inhibitors in delineating signaling pathways in cells, it is 
critical to understand the potential off-target effects that may incorrectly attribute protein 
function to a pathway. The identification of the PI3K/Akt/mTOR pathway as a putative target 
of CX-4945 raises questions about the precise mechanisms of action of CX-4945 in cells. 
There is previous literature which suggests that CX-4945 can down-regulate the 
PI3K/Akt/mTOR pathway (51, 54, 189): however, in this thesis comparative investigation 
using another unrelated CK2 inhibitor revealed differential effects on this pathway. In 
particular, treatment with CX-4945 and Inhibitor VIII displayed differences in the 
phosphorylation of 4E-BP1, although both inhibitors decreased the phosphorylation of 
EIF2S2 Ser2. The phosphorylation status of substrates of kinases is one approach that has 
been utilized to understand drug-target engagement in cells but is considered an indirect 
read-out. A recent study proposed an innovative assay as an alternative strategy in drug 
discovery to examine drug-target engagement in cells, cell extracts and tissues. The cellular 
thermal shift assay (CETSA) relies on the biophysical concept of ligand-induced thermal 
stabilization of proteins and enables the assessment of drug binding to a protein (216). By 
incubating aliquots of cell lysate with a drug and subjecting each aliquot to a different 
temperature, the amount of the target protein of interest that remains soluble can be measured 
and a thermal melt curve can be calculated. Stabilization of the target protein by the drug will 
result in a shifted melt curve, and can be used to identify drug-target protein interaction. This 
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application can be adapted for western blotting or in micro-titer plates for increased 
throughput (217). Recent developments in mass spectrometry technology coupled with 
tandem mass tag labeling reagents have also enabled the monitoring of several thousand 
proteins and the respective melt curves in response to inhibitor treatment (218).  This 
analysis identified ferrochelatase as a novel target of vemurafenib and alectinib, highlighting 
a previously unreported mechanism of action that explains known photosensitivity side 
effects. Although the application of thermal proteome profiling by mass spectrometry 
requires the use of specific mass spectrometry instrumentation and reagents, it would be 
feasible on a smaller scale to begin to study the effect of CX-4945 on constituents of the 
PI3K/Akt/mTOR pathway by utilizing protein specific antibodies in an adaption of CETSA 
for western blotting.  
5.4.2 Investigating the CK2-dependent Phosphoproteome Using Cells Engineered to 
express CX-4945-resistant CK2  
The phosphoproteomics workflow investigating the effect of CX-4945 treatment on HeLa 
cells presented in this thesis identified its broad impact on the phosphoproteome. Considering 
that CX-4945 treatment resulted in the regulation of several different kinases, it would be of 
interest to be able to delineate which of the signaling events observed are indirect effects of 
CK2 inhibition as opposed to off-targets. Another factor in the CK2 field that has been  
underappreciated is the ability to discriminate between the isoform specificity of CK2α and 
CK2α phosphorylation, as CX-4945 can inhibit both isoforms (44). In an effort to understand 
the structural basis of CK2 inhibition by ATP-competitive inhibitors, previous studies have 
identified critical residues in the ATP-binding pocket of CK2α, including Val66 and Ile174 
that are essential for inhibitor binding. Furthermore, mutation of these residues to alanine 
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resulted in resistance to binding with a number of CK2 inhibitors while retaining catalytic 
activity (219).  In the case of CX-4945, structural studies have also revealed an important 
role of His160 for interactions between CK2α and CX-4945 (or His161 in the case of 
CK2α’). Increased resistance to treatment with CX-4945 is achieved by substituting His160 
(or His161) to glutamic acid or aspartic acid in combination with Val66Ala/Ile174/Ala 
substitutions. These studies have inspired efforts in our laboratory to devise chemical 
proteomic strategies to investigate cellular targets of CK2 inhibitors (18). In addition, this 
information has also been exploited to generate cell lines harboring inhibitor-resistant forms 
of CK2α and CK2α’, that are dramatically less sensitive to a number of CK2 inhibitors 
including CX-4945 and Inhibitor VIII treatment.  
The work that is described in this thesis utilized duplex SILAC to enable relative 
quantification of peptides derived from CX-4945 treated cells versus control cells. This 
approach utilized labeling one set of cells with arginine (13C6) and lysine (4,4,5,5-d4) 
resulting in mass shifts of 6 and 4 Da respectively in comparison to normal isotope encoded 
amino acids. To extend these studies, triplex SILAC-based phosphoproteomics can be 
employed using the cell lines harboring inhibitor resistant forms of CK2 to distinguish 
between direct and indirect CK2 signaling events as well as characterizing off-target effects 
(Figure 5.1). Utilizing a third set of labeled arginine (13C6 15N4) and lysine (13C6 15N2) which 
would result in mass shifts of 10 and 8 Da respectively, a population of inhibitor-resistant 
cells treated with CX-4945 could be compared to DMSO and CX-4945 wild-type treated 
cells, enabling the identification of phosphopeptides that are affected by the inhibitor in the 
presence of the inhibitor-resistant forms of CK2. Furthermore, comparison of datasets 
obtained from inhibitor-resistant CK2α and CK2α’ cells could identify sets of 
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phosphorylation sites that are differentially regulated, indicating isoform-specific substrates. 
Related experiments utilizing a triplex SILAC approach could also take advantage of 
different classes of CK2 inhibitors, such as those that target unique features outside of the 
ATP-binding pocket (220) or which abrogate the stability of the tetrameric holo-enzyme 
complex of CK2 (221). This would enable the identification of phosphorylation sites on 
substrates that require tetrameric CK2. Overall, the development of inhibitor-resistant cell 
lines presents interesting opportunities for studying CK2-dependent signaling events under 
different biological contexts and will greatly aid in the characterization of cellular processes 
regulated by CK2. 
5.4.3 Targeted Profiling of CK2-dependent Phosphoproteome Using Mass 
Spectrometry 
The identification of phosphorylation sites that display dynamic de-phosphorylation 
in response to CX-4945 will serve as a useful panel of activity markers upon which a targeted 
strategy to monitor the actions of CX-4945 can be developed. As these phosphorylation sites 
are derived from phosphopeptides that were detected using data-dependent acquisition 
methods, the likelihood of successfully developing a targeted mass spectrometry assay to 
profile CK2 activity is high (222). Historically, selected reaction monitoring (SRM) (also 
referred to as multiple reaction monitoring (MRM)) has been used as the gold standard for 
profiling proteotypic peptides (223). Further advances in mass spectrometry instrumentation 
have enabled the utilization of a similar technique termed parallel reaction monitoring (PRM) 
that can be performed on hybrid quadrupole-orbitrap instruments, such as the Q Exactive 
(224, 225). The advantage of PRM lies within the ability to simultaneously monitor all 
fragment ions from a precursor ion selected in MS1 with high resolution and high mass 
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accuracy in comparison to SRM, and does not require a priori optimization of precursor and 
fragment ion transitions. A recent application of a targeted PRM assay demonstrated the 
utility of using a panel of isotopically-labeled synthetic phosphopeptides as a readout for a 
phosphorylation signature that could be used to monitor the effect of different chemical 
inhibitors (226). PRM assays could also be used to monitor the activity of individual kinases 
in particular contexts. In this respect, proteomic investigations have identified CK2 
phosphorylation sites that increase in response to stimuli such as DNA damage (35, 36), 
metformin (227), and vemurafenib (85) that could be monitored using PRM strategies. 
Therefore, synthesis of isotopically-labeled phosphopeptides that are representative of CK2 
activity could be used to systemically profile CK2 activity using a PRM assay in cells treated 
with DNA damaging agents or potentially in different biological contexts. Considering the 
therapeutic potential of CK2 as a clinically relevant target, a panel of targeted 
phosphopeptides could be used to profile samples derived from patient tissues receiving CX-
4945 to assess treatment efficacy or efficacy of new CK2 inhibitors as they emerge in the 
literature. 
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Figure 5.1 Comparative Phosphoproteomic Analysis Using Inhibitor-Resistant Cells to 
Identify Bona Fide Effects of CK2 and Bona Fide CK2-independent Effects of CX-4945. 
Cells harboring inhibitor-resistant forms of CK2 treated with CX-4945 can be compared 
directly to wild-type cells in a triplex SILAC approach. Quantification of phosphopeptides 
representing bona fide CK2 substrates or CK2-dependent phosphorylation sites will remain 
comparable in abundance between wild-type cells (WT) treated with DMSO and inhibitor-
resistant cells (IR) treated with CX-4945.  Bona fide CK2-independent effects of CX-4945 
will be discernable as quantification of these phosphopeptides will differ between DMSO 
treated wild-type cells and CX-4945 treated inhibitor resistant cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
161 
5.5 Conclusion 
The dynamic nature of protein phosphorylation as mediated by the activity of kinases 
and phosphatases renders it a critical posttranslational modification in the regulation of 
biological processes. The emergence of protein kinase CK2 as a therapeutic target has been 
met with the development of several inhibitors including CX-4945, a small molecule ATP-
competitive inhibitor that has progressed into clinical trial. Furthermore, CX-4945 has been 
used widely in the literature in different models of cancer but these reports are anecdotal in 
terms of the specific signaling pathways that were studied in isolated biological contexts. 
Unbiased proteomic characterization of the effect of CX-4945 in human cells was undertaken 
in order to understand the scope of its impact on the phosphoproteome and the kinome. These 
studies enabled the identification of markers of CK2 activity, which can have applications for 
characterizing future CK2 inhibitors and also identified putative CK2-independent effects of 
CX-4945. The identification of CK2-independent effects raises speculation about the 
mechanism of action of CX-4945 in cells and highlights the need within the CK2 research 
community and the larger kinome research community for well-characterized chemical 
probes and complementary model systems in which to test hypotheses.  
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